



(51) International Patent Classification:

C12N 5/0783 (2010.01) A61K 39/00 (2006.01)
C12N 5/0784 (2010.01) C07K 14/47 (2006.01)
A61K 35/17 (2015.01)

(21) International Application Number:

PCT/US2018/051280

(22) International Filing Date:

17 September 2018 (17.09.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/565,464 29 September 2017 (29.09.2017) US

(71) Applicant: **THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, MSC 7660, Bethesda, Maryland 20892-7660 (US).

(72) Inventors: **MALEKZADEH, Parisa**; 3 Washington Circle NW, Apartment 704, Washington, District of Columbia (US). **ROSENBERG, Steven A.**; 10104 Iron Gate

Road, Potomac, Maryland 20854 (US). **DENIGER, Drew C.**; 10111 Crestwood Road, Kensington, Maryland 20895 (US).

(74) Agent: **LAWLEY, Stephanie M.**; Leydig, Voit & Mayer, Two Prudential Plaza, Suite 4900, 180 North Stetson Avenue, Chicago, Illinois 60601 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION




FIG. 1

(57) Abstract: Disclosed are methods of isolating T cells having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising: inducing autologous APCs of the patient to present the mutated p53 amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated p53 amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of preparing a population of cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.



MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53
CANCER-SPECIFIC MUTATION

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This patent application claims the benefit of U.S. Provisional Patent Application No. 62/565,464, filed September 29, 2017, which is incorporated by reference in its entirety herein.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND
DEVELOPMENT

[0002] This invention was made with Government support under project number ZIABC010984 by the National Institutes of Health, National Cancer Institute. The Government has certain rights in the invention.

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED
ELECTRONICALLY

[0003] Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 687,616 Byte ASCII (Text) file named "740175_ST25.txt," dated September 14, 2018.

BACKGROUND OF THE INVENTION

[0004] Adoptive cell therapy (ACT) can produce positive clinical responses in some cancer patients. Nevertheless, obstacles to the successful use of ACT for the widespread treatment of cancer and other diseases remain. For example, T cells that specifically recognize cancer antigens may be difficult to identify and/or isolate from a patient. Accordingly, there is a need for improved methods of obtaining cancer-reactive T cells.

BRIEF SUMMARY OF THE INVENTION

[0005] An embodiment of the invention provides a method of isolating T cells having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53

mutation, the method comprising: inducing autologous antigen presenting cells (APCs) of a patient to present at least one mutated p53 amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated p53 amino acid sequence; and selecting the autologous T cells that (a) were co-cultured with the autologous APCs that present the mutated p53 amino acid sequence and (b) have antigenic specificity for the mutated p53 amino acid sequence presented in the context of a major histocompatibility complex (MHC) molecule expressed by the patient to provide isolated T cells having antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation.

[0006] Another embodiment of the invention provides a method of isolating a T cell receptor (TCR), or an antigen-binding portion thereof, having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising: isolating T cells having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation according to any of the methods described herein; and isolating a nucleotide sequence that encodes the TCR, or the antigen-binding portion thereof, from the selected autologous T cells, wherein the TCR, or the antigen-binding portion thereof, has antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation.

[0007] Still another embodiment of the invention provides a method of preparing a population of cells that express a TCR, or an antigen-binding portion thereof, having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising: isolating a TCR, or an antigen-binding portion thereof, according to any of the methods described herein, and introducing the nucleotide sequence encoding the isolated TCR, or the antigen-binding portion thereof, into peripheral blood mononuclear cells (PBMC) to obtain cells that express the TCR, or the antigen-binding portion thereof.

[0008] Another embodiment of the invention provides method of preparing a population of T cells that have antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising: isolating T cells according to any of the methods described herein, and expanding the numbers of selected autologous T cells to obtain a population of T cells that have antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation.

[0009] Additional embodiments of the invention provide related populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

[0010] Figure 1 is a graph showing the number of IFN- γ positive spots per 2×10^4 effector cells measured following co-culture of effector cells and target cells. The effector cells were TIL fragment F12, infusion bag TIL (Rx1) from patient 4141, p53-R175H-specific TCR-transduced cells, or mock transduced T cells from patient 4196. The target cells were HLA-A*02:01 APCs (autologous to patient 4141) that were either (1) electroporated with TMGs composed of irrelevant (IRR; left hatched gray bars), WT p53 (p53wt-TMG; right hatched gray bars) or mutated p53 (p53-mut-TMG; gray bars) sequences or (2) pulsed with peptide vehicle (DMSO; left hatched black bars) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R175 sequence (LP-p53-wt-R175; right hatched black bars) or mutated p53-R175H (LP-p53-mut-R175H; black bars) sequence. T cells only (no target; open bars) was negative control and Phorbol 12-myristate 13-acetate (PMA) and Ionomycin (Iono) was positive control (lattice bars).

[0011] Figure 2 is a graph showing the percentage of 4-1BB+ cells (% of CD4+) detected following co-culture of TIL fragments (F14, F20 or F24) from patient 4130 with autologous APCs (1) electroporated with TMGs composed of irrelevant (IRR; open bars), WT p53 (p53-WT; horizontal black bars) or mutated p53 (p53-MUT; gray bars) sequences or (2) pulsed with peptide vehicle (DMSO; left hatched black bars) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R273 sequence (LP-p53-R273-WT; left hatched gray bars) or mutated p53-R273H (LP-p53-R273H-MUT; black bars) sequence.

[0012] Figure 3 is a graph showing the number of IFN- γ positive spots per 2×10^4 effector cells measured following co-culture of TIL fragments (F1-6, F9, F13-23, n=18) from patient 4259 with autologous APCs electroporated with TMGs composed of irrelevant (IRR; open bars), WT p53 (p53-WT; gray bars) or mutated p53 (p53-MUT; black bars) sequences.

[0013] Figure 4 is a graph showing the percentage of 4-1BB+ cells (% of CD4+) detected following co-culture of TIL fragments (F1-F6, F9, F13-F23, n=18) from patient 4259 with autologous APCs electroporated with TMGs composed of irrelevant (IRR; open bars), WT p53 (p53-WT; gray bars) or mutated p53 (p53-MUT; black bars) sequences.

[0014] Figure 5 is a graph showing the percentage of 4-1BB+ cells (% of CD8+) detected following co-culture of TIL fragments (F1-F6, F9, F13-F23, n=18) from patient 4259 with

autologous APCs electroporated with TMGs composed of irrelevant (IRR; open bars), WT p53 (p53-WT; gray bars) or mutated p53 (p53-MUT; black bars) sequences.

[0015] Figure 6 is a graph showing the number of IFN- γ positive spots per 2×10^4 effector cells measured following co-culture of TIL fragments (F1-F6, F9, F13-23, n=18) from patient 4259 with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-Y220 sequence (LP-p53-Y220-WT; gray bars) or mutated p53-Y220C (LP-p53-Y220C-MUT; black bars) sequence.

[0016] Figure 7 is a graph showing the percentage of 4-1BB+ cells (% of CD4+) detected following co-culture of TIL fragments (F1-F6, F9, F13-F23, n=18) from patient 4259 with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-Y220 sequence (LP-p53-Y220-WT; gray bars) or mutated p53-Y220C (LP-p53-Y220C-MUT; black bars) sequence.

[0017] Figure 8 is a graph showing the percentage of 4-1BB+ cells (% of CD8+) detected following co-culture of TIL fragments (F1-F6, F9, F13-F23, n=18) from patient 4259 with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-Y220 sequence (LP-p53-Y220-WT; gray bars) or mutated p53-Y220C (LP-p53-Y220C-MUT; black bars) sequence.

[0018] Figure 9 is a graph showing the number of IFN- γ positive spots per 2×10^4 effector cells measured following co-culture of TIL from patient 4127 with allogeneic (DRB3*01:01:01 or DRB3*02:02:01) APCs which were (1) electroporated with TMGs composed of irrelevant (IRR; left hatched open bars) WT p53 (p53-WT; left hatched gray bars) or mutated p53 (p53-MUT; gray bars) sequences or (2) pulsed with peptide vehicle (DMSO; right hatched open bars) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-G245 sequence (LP-p53-wt-G245; right hatched gray bars) or mutated p53-G245S (LP-p53-mut-G245S; black bars) sequence.

[0019] Figure 10 is a graph showing the number of IFN- γ positive spots per 2×10^4 effector cells measured following co-culture of T cells expressing the 4127-TCR1 with allogeneic (DRB3*01:01:01 or DRB3*02:02:01) APCs which were (1) electroporated with TMGs composed of irrelevant (IRR; left hatched open bars), WT p53 (p53-WT; left hatched gray bars) or mutated p53 (p53-MUT; gray bars) sequences or (2) pulsed with peptide vehicle (DMSO; right hatched open bars) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-G245 sequence (LP-p53-wt-G245; right hatched gray bars) or mutated p53-G245S (LP-p53-mut-G245S; black bars) sequence.

[0020] Figure 11 is a graph showing the number of IFN- γ -positive spots per 2×10^4 effector cells measured following co-culture of TIL fragments (F1-F24, n=24) from patient 4273 with autologous APCs electroporated with TMG (TMG) composed of irrelevant (IRR; open bars) WT p53 (p53-WT; gray bars) or mutated p53 (p53-MUT; black bars) sequence.

[0021] Figure 12 is a graph showing the percentage of 4-1BB+ (% of CD4+) cells detected following co-culture of patient 4273 TIL fragments F1-F24 (n=24) with autologous APCs electroporated with TMG composed of irrelevant (IRR; open bars) WT p53 (p53-WT; gray bars) or mutated p53 (p53-MUT; black bars) sequence.

[0022] Figure 13 is a graph showing the number of IFN- γ -positive spots per 2×10^4 effector cells measured following co-culture of TIL fragments (F1-F24, n=24) from patient 4273 with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-R248 sequence (LP-p53-R248-WT; gray bars) or mutated p53-R248W (LP-p53-R248W-MUT; black bars) sequence.

[0023] Figure 14 is a graph showing the percentage of 4-1BB+ (% of CD4+) cells detected following co-culture of TIL fragments (F1-F24, n=24) from patient 4273 with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-R248 sequence (LP-p53-R248-WT; gray bars) or mutated p53-R248W (LP-p53-R248W-MUT; black bars) sequence.

[0024] Figure 15 is a graph showing the number of IFN- γ -positive spots per 2×10^4 effector cells measured following co-culture of autologous PBL from patient 4149 (transposed with 4149-TCRa2b1 or 4149-TCRa2b2) with autologous APCs which were (1) electroporated with TMG composed of irrelevant (IRR; right hatched black bars), WT p53 (p53-wt-TMG; left hatched black bars) or mutated p53 (p53-mut-TMG; gray bars) sequence or (2) pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-Y220 sequence (LP-p53-Y220-WT; horizontal hatched black bars) or mutated p53-Y220C (LP-p53-Y220C-MUT; black bars) sequence. Phorbol 12-myristate 13-acetate (PMA) and Ionomycin (Iono) was positive control (gray bars).

[0025] Figure 16 is a graph showing the percentage of 4-1BB+ (% of CD4+) cells detected following co-culture of autologous PBL from patient 4149 that were transposed with a TCR (4149-TCRa2b1 or 4149-TCRa2b2) with autologous APCs which were (1) electroporated with TMG composed of irrelevant (IRR; right hatched black bars), WT p53 (p53-wt-TMG; left hatched black bars), or mutated p53 (p53-mut-TMG; gray bars) sequence or (2) pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25-amino

acid peptides composed of WT p53-Y220 sequence (LP-p53-Y220-WT; horizontal hatched black bars) or mutated p53-Y220C (LP-p53-Y220C-MUT; black bars) sequence. PMA and Iono was positive control (gray bars).

[0026] Figure 17 is a graph showing the percentage of 4-1BB⁺ cells (% of CD4⁺ T cells) detected following co-culture of TIL from patient 4149 with autologous DCs pulsed with one of the peptides of Table 10.

[0027] Figure 18 is a graph showing IFN- γ secretion (pg/mL) following co-culture of 4149-TCRa2b2 transposed T cells with Cos7 cells co-transfected with individual HLA alleles +/- TMGs. Cells not transfected with TMG were pulsed with p53Y220C 15-mer peptide. Pulsed target cells are indicated by shaded bars. Target cells transfected with TMG are indicated by unshaded bars.

[0028] Figure 19 is a graph showing the percentage of 4-1BB⁺ (% of CD8⁺) cells detected following co-culture of TIL fragments (F2 and F24) from patient 4213 with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25-amino acid peptides composed of the mutated p53-R248Q (LP-p53-R248Q-MUT; black bars) sequence.

[0029] Figure 20 is a graph showing the number of IFN- γ -positive spots per 2×10^4 effector cells measured following co-culture of CD4⁺ T cells from patient 4213 with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25-amino acid peptides composed of the mutated p53-R248Q (LP-p53-R248Q-MUT; black bars) sequence. Secretion of IFN- γ is shown by open bars. Expression of 4-1BB is shown by closed bars.

[0030] Figure 21 is a graph showing the number of IFN- γ -positive spots per 2×10^4 effector cells measured following co-culture of TIL fragments (F1-F24, n=24) from patient 4268 with autologous APCs electroporated with TMG composed of irrelevant (IRR; open bars), WT p53 (p53-WT; gray bars), or mutated p53 (p53-MUT; black bars) sequence.

[0031] Figure 22 is a graph showing the number of IFN- γ -positive spots per 2×10^4 effector cells measured following co-culture of TIL fragments (F1-F24, n=24) from patient 4268 with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-R248 sequence (LP-p53-R248-WT; gray bars) or mutated p53-R248Q (LP-p53-R248Q-MUT; black bars) sequence.

[0032] Figure 23 is graph showing the percentage of 4-1BB⁺ cells (% of CD4⁺) detected following co-culture of TIL fragments (F1-F24, n=24) from patient 4268 with autologous

APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-R248 sequence (LP-p53-R248-WT; gray bars) or mutated p53-R248Q (LP-p53-R248Q-MUT; black bars) sequence.

[0033] Figure 24 is a graph showing the percentage of 4-1BB⁺ cells (% of CD8⁺) detected following co-culture of TIL fragments (F1-F24, n=24) from patient 4268 with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-R248 sequence (LP-p53-R248-WT; gray bars) or mutated p53-R248Q (LP-p53-R248Q-MUT; black bars) sequence.

[0034] Figure 25 is a graph showing the number of IFN- γ -positive spots per 2×10^4 effector cells measured following co-culture of TIL fragments (F1-F24, n=24) from patient 4266 with autologous APCs electroporated with TMG composed of irrelevant (IRR; open bars), WT p53 (p53-WT; gray bars), or mutated p53 (p53-MUT; black bars) sequence.

[0035] Figure 26 is a graph showing the percentage of 4-1BB⁺ cells (% of CD8⁺) detected following co-culture of TIL fragments (F1-F24, n=24) from patient 4266 with autologous APCs electroporated with TMG composed of irrelevant (IRR; open bars), WT p53 (p53-WT; gray bars), or mutated p53 (p53-MUT; black bars) sequence.

[0036] Figure 27 is a graph showing the number of IFN- γ -positive spots per 2×10^4 effector cells measured following co-culture of TIL fragments (F1-F24, n=24) from patient 4266 with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-R248 sequence (LP-p53-R248-WT; gray bars) or mutated p53-R248W (LP-p53-R248W-MUT; black bars) sequence.

[0037] Figure 28 is a graph showing the percentage of 4-1BB⁺ cells (% of CD8⁺) detected following co-culture of TIL fragments (F1-F24, n=24) from patient 4266 with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-R248 sequence (LP-p53-R248-WT; gray bars) or mutated p53-R248W (LP-p53-R248W-MUT; black bars) sequence.

[0038] Figure 29 is a graph showing the percentage of 4-1BB⁺ cells (% of CD8⁺) detected following co-culture of TIL from patient 4266 with Cos7 cells which were co-transfected with individual HLA alleles from patient 4266 and pulsed with no peptide (open bars), DMSO (peptide vehicle; gray bars), WT p53-R248 peptide (gray hatched bars) or mutated p53-R248W peptide (black bars). Data are mean \pm SEM (n=3).

[0039] Figure 30 is a graph showing the percentage of 4-1BB⁺ cells (% of CD8⁺) detected following co-culture of T cells expressing mock (no TCR), 4266-TCR1, 4266-

TCR2, 4266-TCR3 or 4266-TCR4 with autologous APCs which were pulsed with peptide vehicle (DMSO; gray bars) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R248 sequence (hatched gray bars) or mutated p53-R248W (black bars) sequence. Media alone (open bars) and PMA and Ionomycin (lattice bars) were negative and positive controls, respectively.

[0040] Figure 31 is a graph showing the percentage of 4-1BB+ cells (% of CD8+) detected following co-culture of T cells expressing mock (no TCR) or p53-R248W-specific TCRs (4266-TCR2, 4266-TCR3 or 4266-TCR4) with tumor cell (TC) line established from xenografted tumor fragment resected from Patient 4266 then serially passaged through immunocompromised mice (TC#4266). The TC#4266 cells were either incubated with nothing (black bars), W6/32 pan-HLA Class-I specific blocking antibody (right gray hatched bars), IVA12 pan-HLA Class-II specific blocking antibody (gray bars) or mutated p53-R248W peptide (left gray hatched bars). Media alone (no TC; open bars) and PMA and Ionomycin (gray lattice bars) were negative and positive controls, respectively.

[0041] Figure 32 shows an alignment of the amino acid sequences of the nine p53 splice variants. SP|P04637|P53_HUMAN (SEQ ID NO: 1); SP|P04637-2|P53_HUMAN (SEQ ID NO: 535); SP|P04637-3|P53_HUMAN (SEQ ID NO: 536); SP|P04637-4|P53_HUMAN (SEQ ID NO: 537); SP|P04637-5|P53_HUMAN (SEQ ID NO: 538); SP|P04637-6|P53_HUMAN (SEQ ID NO: 539); SP|P04637-7|P53_HUMAN (SEQ ID NO: 540); SP|P04637-8|P53_HUMAN (SEQ ID NO: 541); and SP|P04637-9|P53_HUMAN (SEQ ID NO: 542).

[0042] Figure 33 is a graph showing the percentage of 4-1BB+ cells (% of CD8+) detected following co-culture of TIL from patient 4273 with autologous APCs which were transfected with TMG encoding irrelevant mutations (gray bars), WT p53 sequences (gray hatched bars) or mutated p53 sequences including p53-R248W (black bars). Media alone (open bars) and PMA and Ionomycin (lattice bars) were negative and positive controls, respectively.

[0043] Figure 34 is a graph showing the percentage of 4-1BB+ cells (% of CD4+) detected following co-culture of TIL from patient 4273 with autologous APCs which were pulsed with 25 amino acid peptides corresponding to the WT (open circles) or mutated (closed squares) from the p53-R248W neoepitope. DMSO was peptide vehicle.

[0044] Figure 35 is a graph showing the percentage of 4-1BB+ cells (% of CD4+) detected following co-culture of TIL from patient 4273 with autologous APCs pulsed with 15

amino acid peptides from the p53-R248W neoepitope (amino acid substitution in bold) overlapping 14 amino acids. DMSO was peptide vehicle, media alone (T cells only) and PMA and ionomycin were controls. The 25 amino acid peptides (wt p53-R248 and mutated p53-R248W) were additional controls for the 15 amino acid peptides. The peptides are: YMCNSSCMGGMNWRP (SEQ ID NO: 592); MCNSSCMGGMNWRPI (SEQ ID NO: 593); CNSSCMGGMNWRPIL (SEQ ID NO: 594); NSSCMGGMNWRPILT (SEQ ID NO: 595); SSCMGGMNWRPILTI (SEQ ID NO: 596); SCMGGMNWRPILTII (SEQ ID NO: 597); CMGGMNWRPILTIIT (SEQ ID NO: 598); MGGMNWRPILTIITL (SEQ ID NO: 599); GGMNWRPILTIITLE (SEQ ID NO: 600); GMNWRPILTIITLED (SEQ ID NO: 601); and MNWRPILTIITL^EDS (SEQ ID NO: 602).

[0045] Figure 36 is a graph showing the concentration of IFN- γ (pg/mL) secreted following co-culture of TIL from Patient 4273 with Cos7 cells co-transfected with individual HLA alleles from patient 4273 and either WT (open bars) or mutated (black bars) TP53 TMG with or without the p53-R248W neoantigen, respectively.

[0046] Figure 37 is a graph showing the number of IFN- γ spots per 2×10^4 cells measured following co-culture of T cells expressing mock (no TCR) or 4273-TCR1a2 with autologous APCs which were pulsed with peptide vehicle (DMSO; gray bars) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R248 sequence (hatched gray bars) or mutated p53-R248W (black bars) sequence. Media alone (open bars) and PMA and Ionomycin (lattice bars) were negative and positive controls, respectively.

[0047] Figure 38 is a graph showing the percentage of 4-1BB⁺ cells (% of CD4⁺) detected following co-culture of TIL fragment F1, F3, F7 or F19 from patient 4252 with autologous APCs (immature DCs) that were either (1) electroporated with TMGs composed of irrelevant (IRR; left hatched gray bars), WT p53 (p53wt-TMG; right hatched gray bars) or mutated p53 (p53-mut-TMG; gray bars) sequences or (2) pulsed with peptide vehicle (DMSO; left hatched black bars) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R175 sequence (LP-p53-wt-R175; right hatched black bars) or mutated p53-R175H (LP-p53-mut-R175H; black bars) sequence. T cells only (no target; open bars) was negative control and PMA and Iono was positive control (lattice bars). Data are mean \pm SEM (n=3). Student's t-tests were performed between indicated groups by line. *p<0.05, **p<0.01, ***p<0.001.

[0048] Figure 39 is a graph showing the number of IFN- γ spots per 2×10^4 cells measured following co-culture of TIL fragment F13 or F16 from patient 4270 with autologous APCs

(immature DCs) that were either (1) electroporated with TMGs composed of irrelevant (IRR; left hatched gray bars), WT p53 (p53wt-TMG; right hatched gray bars) or mutated p53 (p53-mut-TMG; gray bars) sequences or (2) pulsed with peptide vehicle (DMSO; left hatched black bars) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R282 sequence (LP-p53-wt-R282; right hatched black bars) or mutated p53-R282W (LP-p53-mut-R282W; black bars) sequence. T cells only (no target; open bars) was negative control and PMA and Iono was positive control (lattice bars). Data are mean \pm SEM (n=3).

[0049] Figure 40 is a graph showing the number of IFN- γ spots per 2×10^4 cells measured following co-culture of TIL fragments (F1-F24, n=18) from patient 4285 with autologous APCs electroporated with TMGs composed of irrelevant (IRR; open bars), WT p53 (p53-WT; gray bars) or mutated p53 (p53-MUT; black bars) sequences.

[0050] Figure 41 is a graph showing the number of IFN- γ spots per 2×10^4 cells measured following co-culture of TIL fragments (F1-F24, n=18) from patient 4285 with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R175 sequence (LP-p53-R175-WT; gray bars) or mutated p53-R175H (LP-p53-R175H-MUT; black bars) sequence.

[0051] Figure 42 is a graph showing the percentage of 4-1BB+ cells (% of CD4+) detected following co-culture of TIL fragments (F1-F24, n=18) from patient 4285 with autologous APCs electroporated with TMGs composed of irrelevant (IRR; open bars) WT p53 (p53-WT; gray bars) or mutated p53 (p53-MUT; black bars) sequences.

[0052] Figure 43 is a graph showing the percentage of 4-1BB+ cells (% of CD4+) detected following co-culture of TIL fragments (F1-F24, n=18) from patient 4285 with autologous APCs pulsed with peptide vehicle (DMSO; open bars) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R175 sequence (LP-p53-R175-WT; gray bars) or mutated p53-R175H (LP-p53-R175H-MUT; black bars) sequence.

[0053] Figure 44 is a graph showing the overall mutation frequency (%) of each missense p53 mutation located at the indicated p53 codons in 141 epithelial tumors sequenced.

[0054] Figure 45 is a graph showing the percentage of 4-1BB positive cells (% of CD8+) (right y-axis; black bars) and IFN- γ (spots per 2×10^4 cells) (left y-axis; hatched bars) measured following co-culture of TIL from Patient 4141 (fragment culture 12) with autologous APCs transfected with TMG encoding irrelevant mutations (TMG-IRR), WT p53 sequence (TP53-wt-TMG) or mutated p53 sequence including R175H (TP53-mut-TMG). Media alone and PMA and ionomycin were negative and positive controls, respectively.

[0055] Figure 46 is a graph showing the number of IFN- γ -positive spots per 2×10^4 effector cells measured following co-culture of TIL from Patient 4141 (fragment culture 12) with Cos7 cells co-transfected with the indicated HLA alleles and either no extra gene (HLA only; open bars), WT TP53 TMG (gray hatched bars), or mutated (black bars) TP53 TMG containing the p53-R175H sequence.

[0056] Figure 47 is a graph showing the concentration of IFN- γ (pg/mL) measured following co-culture of T cells expressing mock (no TCR) or 4141-TCR1a2 with T2 tumor cells (expressing HLA-A*02:01). T2 cells were pulsed with peptide vehicle (DMSO; gray bars) or purified (>95% by HPLC) peptides composed of WT p53-R175 peptide (hatched gray bars) or mutated p53-R175H peptide (black bars). Media alone (open bars) and PMA and Ionomycin (lattice bars) were negative and positive controls, respectively. Data are mean \pm SEM (n=3).

[0057] Figure 48 is a graph showing the percentage of cells positive for expression of one of the indicated markers following co-culture of T cells expressing 4141-TCR1a2 with Saos2 cells (p53-NULL and HLA-A*02:01+), which were either unmanipulated (unshaded bars) or made to overexpress full length p53-R175H protein (shaded bars). Data are mean \pm SEM (n=3). Student's two-tailed t-tests were performed for each cytokine between the two cell lines for statistical analyses (**p<0.001).

[0058] Figure 49 is a graph showing the percentage of CD4+4-1BB positive cells detected following co-culture of TIL (fragment culture 6 from patient 4259) with autologous APCs either (1) electroporated with TMG composed of irrelevant (TMG-IRR), WT p53 (TMG-p53-WT) or mutated p53 (TMG-p53-MUT) sequence or (2) pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-Y220 sequence (LP-p53-Y220-WT) or mutated p53-Y220C (LP-p53-Y220C-MUT) sequence.

[0059] Figure 50 is a graph showing the percentage of CD4+4-1BB positive cells detected following co-culture of TIL fragment culture (no. 6) from patient 4259 with autologous APCs pulsed with decreasing concentrations of 25-amino acid peptides corresponding to the WT p53 sequence (open circles) or mutated p53-Y220C (closed squares) for 2 hours at 37 °C.

[0060] Figure 51 is a graph showing the percentage of CD4+4-1BB positive cells detected following co-culture of TIL from patient 4259 with autologous APCs pulsed with DMSO, WT p53-Y220 peptide, or mutated p53-Y220C peptide.

[0061] Figure 52 is a graph showing the percentage of 4-1BB positive cells (% of CD4+) detected following co-culture of TIL fragment culture no. 6 from Patient 4259 with Cos7 cells co-transfected with the indicated HLA alleles from patient 4259 and pulsed with DMSO (open bars) or the p53-Y220C peptide (closed bars).

[0062] Figure 53 is a graph showing the percentage of 4-1BB+ cells detected following co-culture of TC#4259 target cells (endogenously expressing p53-Y220C and HLA-DRB1*04:01:01) with effector T cells (10^5) expressing mock (no TCR; open bars) or p53-Y220C-specific TCR (4259-F6-TCR; black bars). The TC#4259 cells were either incubated with nothing, W6/32 pan-HLA Class-I specific blocking antibody, IVA12 pan-HLA Class-II specific blocking antibody or mutated p53-Y220C peptide. Media alone (no TC) and PMA and Ionomycin were negative and positive controls, respectively. Data are mean \pm SEM (n=3). Student's two-tailed t-tests were performed between groups as indicated for statistical analyses (**p<0.01 and ***p<0.001).

[0063] Figure 54 is a graph showing the percentage of 4-1BB+ cells (% of CD4+) detected following co-culture of TIL fragment cultures 4285-F6, 4285-F9 and 4285-F10 with Cos7 cells transfected with the indicated HLA alleles and pulsed with DMSO (peptide vehicle; gray and black hatched bars) or mutated p53-R175H peptide (gray, lattice and black bars).

[0064] Figure 55 is a graph showing the percentage of 4-1BB+ cells (% of CD4+) detected following co-culture of T cells transposed with 4285-TCR1 with autologous APCs pulsed with decreasing concentrations of 25- or 15-amino acid peptides corresponding to the WT (open circles and squares) or mutated (closed circles and squares) p53-R175H sequence.

DETAILED DESCRIPTION OF THE INVENTION

[0065] Tumor Protein P53 (also referred to as "TP53" or "p53") acts as a tumor suppressor by, for example, regulating cell division. The p53 protein is located in the nucleus of the cell, where it binds directly to DNA. When DNA becomes damaged, the p53 protein is involved in determining whether the DNA will be repaired or the damaged cell will undergo apoptosis. If the DNA can be repaired, p53 activates other genes to fix the damage. If the DNA cannot be repaired, the p53 protein prevents the cell from dividing and signals it to undergo apoptosis. By stopping cells with mutated or damaged DNA from dividing, p53 helps prevent the development of tumors. Wild-type (WT) full-length p53 comprises the amino acid sequence of SEQ ID NO: 1.

[0066] Mutations in the p53 protein may reduce or eliminate the p53 protein's tumor suppressor function. Alternatively or additionally, a p53 mutation may be a gain-of-function mutation by interfering with wild type p53 in a dominant negative fashion. Mutated p53 protein may be expressed in any of a variety of human cancers such as, for example, cholangiocarcinoma, melanoma, colon cancer, rectal cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), glioblastoma, uterine cervical cancer, head and neck cancer, breast cancer, pancreatic cancer, or bladder cancer.

[0067] An embodiment of the invention provides a method of isolating T cells having antigenic specificity for a p53 mutated amino acid sequence encoded by a cancer-specific p53 mutation. Mutations of p53 are defined herein by reference to the amino acid sequence of full-length, WT p53 (SEQ ID NO: 1). Thus, mutations of p53 are described herein by reference to the amino acid residue present at a particular position, followed by the position number, followed by the amino acid with which that residue has been replaced in the particular mutation under discussion. For example, when the positions are as defined by SEQ ID NO: 1, the term "R175" refers to the arginine present at position 175 of SEQ ID NO: 1, "R175H" indicates that the arginine present at position 175 of SEQ ID NO: 1 is replaced by histidine, while "G245S" indicates that the glycine present at position 245 of SEQ ID NO: 1 has been replaced with serine. P53 has nine known splice variants. The p53 mutations described herein are conserved over all nine p53 splice variants. An alignment of the nine p53 splice variants is shown in Figure 32. Accordingly, T cells isolated by the inventive methods may have antigenic specificity for any mutated p53 amino acid sequence described herein encoded by any of the nine p53 splice variants. When the positions are as defined by SEQ ID NO: 1, then the actual positions of the amino acid sequence of a particular splice variant of p53 are defined relative to the corresponding positions of SEQ ID NO: 1, and the positions as defined by SEQ ID NO: 1 may be different than the actual positions in a particular splice variant. Thus, for example, mutations refer to a replacement of an amino acid residue in the amino acid sequence of a particular splice variant of p53 corresponding to the indicated position of the 393-amino acid sequence of SEQ ID NO: 1 with the understanding that the actual positions in the splice variant may be different.

[0068] Embodiments of the invention may provide any one or more of many advantages. Mutated p53 is expressed by cancer cells and is not expressed by normal, noncancerous cells. Without being bound to a particular theory or mechanism, it is believed that T cells isolated by the inventive methods advantageously target the destruction of cancer cells while

minimizing or eliminating the destruction of normal, non-cancerous cells, thereby reducing, for example, by minimizing or eliminating, toxicity. Moreover, T cells isolated by the inventive methods may, advantageously, successfully treat or prevent mutated p53-positive cancers that do not respond to other types of treatment such as, for example, chemotherapy, surgery, or radiation. Additionally, T cells isolated by the inventive methods may provide highly avid recognition of mutated p53, which may provide the ability to recognize unmanipulated tumor cells (e.g., tumor cells that have not been treated with interferon (IFN)- γ , transfected with a vector encoding one or both of mutated p53 and the applicable HLA molecule, pulsed with a p53 peptide with the p53 mutation, or a combination thereof). Roughly half of all tumors harbor a mutation in p53, about half of which will be a missense mutation and about 30% of the missense mutations occur at the following “hotspot” residues: R175H, Y220C, G245D, G245S, R248L, R248Q, R248W, R249S, R273C, R273L, R273H and R282W. Moreover, the same “hotspot” mutations in p53 (e.g., R175H, Y220C, G245D, G245S, R248L, R248Q, R248W, R249S, R273H, R273C, R273L, or R282W) occur frequently (cumulatively about 30% of the p53 missense mutations) in tumors of unrelated people. Accordingly, T cells isolated by the inventive methods may increase the number of patients who may be eligible for treatment with immunotherapy.

[0069] The inventive methods may be faster, more focused, and more specific as compared to traditional methods of isolating cancer mutation-reactive T cells. Such traditional methods involve identifying gene(s) containing a cancer-specific mutation (e.g., neoantigens) expressed by the patient prior to co-culturing the patient’s autologous T cells with the patient’s autologous antigen presenting cells which present peptides comprising the cancer-specific mutation encoded by the identified gene(s) as described in, for example, US 2017/0218042 and US 2017/0224800 (hereinafter, “traditional screening methods”). With the inventive methods, peptides and tandem minigenes (TMG) including p53 mutations can be produced, stocked and validated prior to screening a patient so that once a p53 mutation is identified in a patient’s tumor, the patient’s T cells can be tested independent of the knowledge of the other mutations in the patient’s tumor. This may reduce the time required to carry out the method which may be particularly advantageous when evaluating terminally ill patients. For example, the duration of the inventive methods may be, e.g., about 3 to about 6 weeks shorter than traditional screening methods. The inventive methods may also provide a highly-focused study of p53 mutation responses in the absence of other competing mutations. Without being bound to a particular theory or mechanism, it is believed that pools

of peptides or competing peptides in patient mutation-derived TMGs (with mutations in proteins other than p53) can interfere with the mutated p53 peptides and could mask a T cell response. Because the inventive methods focus on mutations in only one gene, p53, the inventive methods may provide increased speed and efficiency in the attempt to identify the p53 mutation-specific T cells and TCRs as compared to traditional screening methods, which involve parsing out the neoantigens in the peptide pool or TMG to determine which neoantigen generated the T cell response. The inventive methods may, advantageously, generate T cells and/or TCRs useful for autologous or allogeneic therapy. By focusing on p53 mutations, it may be possible to identify low frequency responses, which may be diluted in the high throughput of traditional screening methods, and may allow for the identification of T cells and TCRs which otherwise would have been lost in the complexity of screening dozens to hundreds of neoantigens. The inventive methods may be useful for testing T cell responses in a patient independent of the knowledge of whether the patient had the corresponding mutation or even a tumor. The inventive methods may be useful for screening patients with a defined HLA haplotype and predicted p53 mutation binding, but are not limited to screening this type of cohort.

[0070] The cancer-specific p53 mutation may be any mutation in the p53 gene which encodes a mutated p53 amino acid sequence (also referred to as a “non-silent mutation”) and which is expressed in a cancer cell but not in a normal, noncancerous cell. Non-limiting examples of cancer-specific p53 mutations include missense, nonsense, insertion, deletion, duplication, frameshift, and repeat expansion mutations. In a preferred embodiment, the p53 mutation is a missense mutation.

[0071] In an embodiment of the invention, the mutated p53 amino acid sequence comprises a human p53 amino acid sequence with a mutation at position 175, 220, 245, 248, 249, 273, or 282 of SEQ ID NO: 1. The p53 mutation may be any missense mutation. Accordingly, the mutation at position 175, 220, 245, 248, 249, 273, or 282 of SEQ ID NO: 1 may be a substitution of the native (WT) amino acid residue present at position 175, 220, 245, 248, 249, 273, or 282 of SEQ ID NO: 1 with any amino acid residue other than the native (WT) amino acid residue present at the particular position under discussion. In an embodiment of the invention, the mutated p53 amino acid sequence comprises a human p53 amino acid sequence with one of the following human p53 mutations: R175H, Y220C, G245D, G245S, R248L, R248Q, R248W, R249S, R273H, R273C, R273L, or R282W. For

example, the mutated p53 amino acid sequence may comprise a mutated p53 amino acid sequence selected from the group consisting of SEQ ID NOs: 2-13.

[0072] The method may comprise inducing autologous antigen presenting cells (APCs) of a patient to present at least one mutated p53 amino acid sequence. The APCs may include any cells which present peptide fragments of proteins in association with major histocompatibility complex (MHC) molecules on their cell surface. The APCs may include, for example, any one or more of macrophages, DCs, langerhans cells, B-lymphocytes, and T-cells. Preferably, the APCs are DCs. By using autologous APCs from the patient, the inventive methods may, advantageously, identify T cells that have antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation that is presented in the context of an MHC molecule expressed by the patient. The MHC molecule can be any MHC molecule expressed by the patient including, but not limited to, MHC Class I, MHC Class II, HLA-A, HLA-B, HLA-C, HLA-DM, HLA-DO, HLA-DP, HLA-DQ, and HLA-DR molecules. The inventive methods may, advantageously, identify mutated p53 amino acid sequences presented in the context of any MHC molecule expressed by the patient without using, for example, epitope prediction algorithms to identify MHC molecules or mutated p53 amino acid sequences, which may be useful only for a select few MHC class I alleles and may be constrained by the limited availability of reagents to select p53 mutation-reactive T cells (e.g., an incomplete set of MHC tetramers). Accordingly, in an embodiment of the invention, the inventive methods advantageously induce APCs to present the mutated p53 amino acid sequences in the context of any MHC molecule expressed by the patient and are not limited to any particular MHC molecule. Preferably, the autologous APCs are antigen-negative autologous APCs.

[0073] Inducing autologous APCs of the patient to present the at least one mutated p53 amino acid sequence may be carried out using any suitable method known in the art. In an embodiment of the invention, inducing autologous APCs of the patient to present the at least one mutated p53 amino acid sequence comprises pulsing the autologous APCs with a peptide comprising no more than one mutated p53 amino acid sequence or a pool of peptides, each peptide in the pool comprising a different mutated p53 amino acid sequence. In this regard, the autologous APCs may be cultured with a peptide or a pool of peptides comprising the mutated p53 amino acid sequence in a manner such that the APCs internalize the peptide(s) and display the mutated p53 amino acid sequence(s), bound to an MHC molecule, on the cell membrane. Methods of pulsing APCs are known in the art and are described in, e.g.,

Solheim (Ed.), *Antigen Processing and Presentation Protocols (Methods in Molecular Biology)*, Human Press, (2010). The peptide(s) used to pulse the APCs may include the mutated p53 amino acid(s) encoded by the cancer-specific p53 mutation. The peptide(s) may further comprise any suitable number of contiguous amino acids from the endogenous p53 protein encoded by the p53 gene on each of the carboxyl side and the amino side of the mutated amino acid(s). The number of contiguous amino acids from the endogenous p53 protein flanking each side of the mutation is not limited and may be, for example, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, or a range defined by any two of the foregoing values. Preferably, the peptide(s) comprise(s) about 12 contiguous amino acids from the endogenous p53 protein on each side of the mutated amino acid(s). In an embodiment, the peptide or pool of peptides comprise(s) one or more of the mutated p53 peptides of SEQ ID NOs: 2-13 (Table 1).

[0074] In an embodiment of the invention, inducing autologous APCs of the patient to present the mutated p53 amino acid sequence comprises introducing a nucleotide sequence encoding the mutated p53 amino acid sequence into the APCs. The nucleotide sequence is introduced into the APCs so that the APCs express and display the mutated p53 amino acid sequence, bound to an MHC molecule, on the cell membrane. The nucleotide sequence encoding the mutated p53 amino acid may be RNA or DNA. Introducing a nucleotide sequence into APCs may be carried out in any of a variety of different ways known in the art as described in, e.g., Solheim et al. *supra*. Non-limiting examples of techniques that are useful for introducing a nucleotide sequence into APCs include transformation, transduction, transfection, and electroporation. In an embodiment, the method may comprise preparing more than one nucleotide sequence, each encoding a different mutated p53 amino acid sequence, and introducing each nucleotide sequence into a different population of autologous APCs. In this regard, multiple populations of autologous APCs, each population expressing and displaying a different mutated p53 amino acid sequence, may be obtained.

[0075] In an embodiment, the method may comprise introducing a nucleotide sequence encoding the more than one mutated p53 amino acid sequence. In this regard, in an embodiment of the invention, the nucleotide sequence introduced into the autologous APCs is a tandem minigene (TMG) construct, each minigene comprising a p53 gene, each p53 gene including a cancer-specific p53 mutation that encodes a different mutated p53 amino acid sequence. Each minigene may encode one p53 mutation flanked on each side of the p53

mutation by any suitable number of contiguous amino acids from the endogenous p53 protein, as described herein with respect to other aspects of the invention. The number of minigenes in the construct is not limited and may include for example, about 5, about 10, about 11, about 12, about 13, about 14, about 15, about 20, about 25, or more, or a range defined by any two of the foregoing values. In an embodiment of the invention, the TMG construct encodes one or more mutated p53 peptides of SEQ ID NOs: 2-13. For example, the TMG construct may encode the amino acid sequence of SEQ ID NO: 14. The APCs express the mutated p53 amino acid sequences encoded by the TMG construct and display the mutated p53 amino acid sequences, bound to an MHC molecule, on the cell membranes. In an embodiment, the method may comprise preparing more than one TMG construct, each construct encoding a different set of mutated p53 amino acid sequences, and introducing each TMG construct into a different population of autologous APCs. In this regard, multiple populations of autologous APCs, each population expressing and displaying mutated p53 amino acid sequences encoded by different TMG constructs, may be obtained.

[0076] The method may comprise culturing autologous T cells of the patient with the autologous APCs that present the mutated p53 amino acid sequence. The T cells can be obtained from numerous sources in the patient, including but not limited to tumor, blood, bone marrow, lymph node, the thymus, or other tissues or fluids. The T cells can include any type of T cell and can be of any developmental stage, including but not limited to, CD4+/CD8+ double positive T cells, CD4+ helper T cells, e.g., Th1 and Th2 cells, CD8+ T cells (e.g., cytotoxic T cells), tumor infiltrating cells (e.g., tumor infiltrating lymphocytes (TIL)), peripheral blood T cells, memory T cells, naïve T cells, and the like. The T cells may be CD8+ T cells, CD4+ T cells, or both CD4+ and CD8+ T cells. The method may comprise co-culturing the autologous T cells and autologous APCs so that the T cells encounter the mutated p53 amino acid sequence presented by the APCs in such a manner that the autologous T cells specifically bind to and immunologically recognize a mutated p53 amino acid sequence presented by the APCs. In an embodiment of the invention, the autologous T cells are co-cultured in direct contact with the autologous APCs.

[0077] The method may comprise selecting the autologous T cells that (a) were co-cultured with the autologous APCs that present the mutated p53 amino acid sequence and (b) have antigenic specificity for the mutated p53 amino acid sequence presented in the context of a MHC molecule expressed by the patient. The phrase “antigenic specificity,” as used herein, means that the autologous T cells can specifically bind to and immunologically

recognize the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation. The selecting may comprise identifying the T cells that have antigenic specificity for the mutated p53 amino acid sequence and separating them from T cells that do not have antigenic specificity for the mutated p53 amino acid sequence. Selecting the autologous T cells having antigenic specificity for the mutated p53 amino acid sequence may be carried out in any suitable manner. In an embodiment of the invention, the method comprises expanding the numbers of autologous T cells, e.g., by co-culturing with a T cell growth factor, such as interleukin (IL)-2 or IL-15, or as described herein with respect to other aspects of the invention, prior to selecting the autologous T cells. In an embodiment of the invention, the method does not comprise expanding the numbers of autologous T cells with a T cell growth factor, such as IL-2 or IL-15 prior to selecting the autologous T cells.

[0078] For example, upon co-culture of the autologous T cells with the APCs that present the mutated p53 amino acid sequence, T cells having antigenic specificity for the mutated p53 amino acid sequence may express any one or more of a variety of T cell activation markers which may be used to identify those T cells having antigenic specificity for the mutated p53 amino acid sequence. Such T cell activation markers may include, but are not limited to, programmed cell death 1 (PD-1), lymphocyte-activation gene 3 (LAG-3), T cell immunoglobulin and mucin domain 3 (TIM-3), 4-1BB, OX40, and CD107a. Accordingly, in an embodiment of the invention, selecting the autologous T cells that have antigenic specificity for the mutated p53 amino acid sequence comprises selecting the T cells that express any one or more of PD-1, LAG-3, TIM-3, 4-1BB, OX40, and CD107a. Cells expressing one or more T cell activation markers may be sorted on the basis of expression of the marker using any of a variety of techniques known in the art such as, for example, fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) as described in, e.g., Turcotte et al., *Clin. Cancer Res.*, 20(2): 331-43 (2013) and Gros et al., *J. Clin. Invest.*, 124(5): 2246-59 (2014).

[0079] In another embodiment of the invention, selecting the autologous T cells that have antigenic specificity for the mutated p53 amino acid sequence comprises selecting the T cells (i) that secrete a greater amount of one or more cytokines upon co-culture with APCs that present the mutated p53 amino acid sequence as compared to the amount of the one or more cytokines secreted by a negative control or (ii) in which at least twice as many of the numbers of T cells secrete one or more cytokines upon co-culture with APCs that present the mutated p53 amino acid sequence as compared to the numbers of negative control T cells that secrete

the one or more cytokines. The one or more cytokines may comprise any cytokine the secretion of which by a T cell is characteristic of T cell activation (e.g., a T cell receptor (TCR) expressed by the T cells specifically binding to and immunologically recognizing the mutated p53 amino acid sequence). Non-limiting examples of cytokines, the secretion of which is characteristic of T cell activation, include IFN- γ , IL-2, and tumor necrosis factor alpha (TNF- α), granulocyte/monocyte colony stimulating factor (GM-CSF), IL-4, IL-5, IL-9, IL-10, IL-17, and IL-22.

[0080] For example, the autologous T cells may be considered to have “antigenic specificity” for the mutated p53 amino acid sequence if the T cells secrete at least twice as much IFN- γ upon co-culture with (a) antigen-negative APCs pulsed with a concentration of a peptide comprising the mutated p53 amino acid sequence (e.g., about 0.05 ng/mL to about 10 μ g/mL, e.g., 0.05 ng/mL, 0.1 ng/mL, 0.5 ng/mL, 1 ng/mL, 5 ng/mL, 100 ng/mL, 1 μ g/mL, 5 μ g/mL, or 10 μ g/mL) or (b) APCs into which a nucleotide sequence encoding the mutated p53 amino acid sequence has been introduced as compared to the amount of IFN- γ secreted by a negative control. The negative control may be, for example, autologous T cells (e.g., derived from peripheral blood mononuclear cells (PBMC)) co-cultured with (a) antigen-negative APCs pulsed with the same concentration of an irrelevant peptide (e.g., the wild-type amino acid sequence, or some other peptide with a different sequence from the mutated p53 amino acid sequence) or (b) APCs into which a nucleotide sequence encoding an irrelevant peptide sequence has been introduced. The autologous T cells may also have “antigenic specificity” for the mutated p53 amino acid sequence if the T cells secrete a greater amount of IFN- γ upon co-culture with antigen-negative APCs pulsed with higher concentrations of a peptide comprising the mutated p53 amino acid sequence as compared to a negative control, for example, the negative control described above. IFN- γ secretion may be measured by methods known in the art such as, for example, enzyme-linked immunosorbent assay (ELISA).

[0081] Alternatively or additionally, the autologous T cells may be considered to have “antigenic specificity” for the mutated p53 amino acid sequence if at least twice as many of the numbers of T cells secrete IFN- γ upon co-culture with (a) antigen-negative APCs pulsed with a concentration of a peptide comprising the mutated p53 amino acid sequence or (b) APCs into which a nucleotide sequence encoding the mutated p53 amino acid sequence has been introduced as compared to the numbers of negative control T cells that secrete IFN- γ . The concentration of peptide and the negative control may be as described herein with respect

to other aspects of the invention. The numbers of cells secreting IFN- γ may be measured by methods known in the art such as, for example, ELISPOT.

[0082] Alternatively or additionally, the autologous T cells may be considered to have “antigenic specificity” for mutated p53 if at least twice as many spots are detected by ELISPOT for the T cells upon co-culture with (a) antigen-negative, applicable HLA molecule positive target cells pulsed with a low concentration of mutated p53 peptide or (b) antigen-negative, applicable HLA molecule positive target cells into which a nucleotide sequence encoding mutated p53 has been introduced such that the target cell expresses mutated p53 as compared to the number of spots detected by ELISPOT for negative control T cells co-cultured with the same target cells. The concentration of peptide and the negative control may be as described herein with respect to other aspects of the invention.

[0083] Alternatively or additionally, the autologous T cells may be considered to have “antigenic specificity” for mutated p53 if greater than about 50 spots are detected by ELISPOT for the T cells expressing the TCR upon co-culture with (a) antigen-negative, applicable HLA molecule positive target cells pulsed with a low concentration of mutated p53 peptide or (b) antigen-negative, applicable HLA molecule positive target cells into which a nucleotide sequence encoding mutated p53 has been introduced such that the target cell expresses mutated p53. The concentration of peptide may be as described herein with respect to other aspects of the invention.

[0084] While T cells having antigenic specificity for the mutated p53 amino acid sequence may both (1) express any one or more T cells activation markers described herein and (2) secrete a greater amount of one or more cytokines as described herein, in an embodiment of the invention, T cells having antigenic specificity for the mutated p53 amino acid sequence may express any one or more T cell activation markers without secreting a greater amount of one or more cytokines or may secrete a greater amount of one or more cytokines without expressing any one or more T cell activation markers.

[0085] In another embodiment of the invention, selecting the autologous T cells that have antigenic specificity for the mutated p53 amino acid sequence comprises selectively growing the autologous T cells that have antigenic specificity for the mutated p53 amino acid sequence. In this regard, the method may comprise co-culturing the autologous T cells with autologous APCs in such a manner as to favor the growth of the T cells that have antigenic specificity for the mutated p53 amino acid sequence over the T cells that do not have antigenic specificity for the mutated p53 amino acid sequence. Accordingly, a population of

T cells is provided that has a higher proportion of T cells that have antigenic specificity for the mutated p53 amino acid sequence as compared to T cells that do not have antigenic specificity for the mutated p53 amino acid sequence.

[0086] In an embodiment of the invention, the method further comprises obtaining multiple fragments of a tumor from the patient, separately co-culturing autologous T cells from each of the multiple fragments with the autologous APCs that present the mutated p53 amino acid sequence as described herein with respect to other aspects of the invention, and separately assessing the T cells from each of the multiple fragments for antigenic specificity for the mutated p53 amino acid sequence, as described herein with respect to other aspects of the invention.

[0087] In an embodiment of the invention in which T cells are co-cultured with autologous APCs expressing multiple mutated p53 amino acid sequences (e.g., multiple mutated p53 amino acid sequences encoded by a TMG construct or multiple mutated p53 amino acid sequences in a pool of peptides pulsed onto autologous APCs), selecting the autologous T cells may further comprise separately assessing autologous T cells for antigenic specificity for each of the multiple mutated p53 amino acid sequences. For example, the inventive method may further comprise separately inducing autologous APCs of the patient to present each mutated p53 amino acid sequence encoded by the construct (or included in the pool), as described herein with respect to other aspects of the invention (for example, by providing separate APC populations, each presenting a different mutated p53 amino acid sequence encoded by the construct (or included in the pool)). The method may further comprise separately co-culturing autologous T cells of the patient with the different populations of autologous APCs that present each mutated p53 amino acid sequence, as described herein with respect to other aspects of the invention. The method may further comprise separately selecting the autologous T cells that (a) were co-cultured with the autologous APCs that present the mutated p53 amino acid sequence and (b) have antigenic specificity for the mutated p53 amino acid sequence presented in the context of a MHC molecule expressed by the patient, as described herein with respect to other aspects of the invention. In this regard, the method may comprise determining which mutated p53 amino acid sequence encoded by a TMG construct that encodes multiple mutated p53 amino acid sequences (or included in the pool) are immunologically recognized by the autologous T cells (e.g., by process of elimination).

[0088] In an embodiment of the invention, the method further comprises expanding the numbers of selected autologous T cells to obtain a population of T cells that have antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation. Expansion of the numbers of selected cells can be accomplished by any of a number of methods as are known in the art as described in, for example, U.S. Patent 8,034,334; U.S. Patent 8,383,099; U.S. Patent Application Publication No. 2012/0244133; Dudley et al., *J. Immunother.*, 26:332-42 (2003); and Riddell et al., *J. Immunol. Methods*, 128:189-201 (1990). In an embodiment, expansion of the numbers of T cells is carried out by culturing the T cells with OKT3 antibody, IL-2, and feeder PBMC (e.g., irradiated allogeneic PBMC). In this regard, the inventive methods may, advantageously, generate a large number of T cells having antigenic specificity for the mutated p53 amino acid sequence.

[0089] The T cells isolated by the inventive methods may be useful for preparing cells for adoptive cell therapies. In this regard, an embodiment of the invention provides a method of preparing a population of T cells that have antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising isolating T cells as described herein with respect to other aspects of the invention, and expanding the numbers of selected autologous T cells to obtain a population of T cells that have antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific mutation. Expanding the numbers of selected cells may be carried out as described herein with respect to other aspects of the invention.

[0090] Another embodiment of the invention provides a method of isolating a T cell receptor (TCR), or an antigen-binding portion thereof, having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation. The method may comprise isolating T cells having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation as described herein with respect to other aspects of the invention.

[0091] The method may further comprise isolating a nucleotide sequence that encodes the TCR, or the antigen-binding portion thereof, from the selected T cells, wherein the TCR, or the antigen-binding portion thereof, has antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation. In an embodiment of the invention, prior to isolating the nucleotide sequence that encodes the TCR, or the antigen-binding portion thereof, the numbers selected T cells that have antigenic specificity for the mutated p53 amino acid sequence may be expanded. Expanding the numbers of selected cells may be

carried out as described herein with respect to other aspects of the invention. In another embodiment of the invention, the numbers of selected T cells that have antigenic specificity for the mutated p53 amino acid sequence are not expanded prior to isolating the nucleotide sequence that encodes the TCR, or the antigen-binding portion thereof. For example, the TCR, or antigen binding portion thereof, may be isolated from a single cell.

[0092] The “the antigen-binding portion” of the TCR, as used herein, refers to any portion comprising contiguous amino acids of the TCR of which it is a part, provided that the antigen-binding portion specifically binds to the mutated p53 amino acid sequence as described herein with respect to other aspects of the invention. The term “antigen-binding portion” refers to any part or fragment of the TCR, which part or fragment retains the biological activity of the TCR of which it is a part (the parent TCR). Antigen-binding portions encompass, for example, those parts of a TCR that retain the ability to specifically bind to the mutated p53 amino acid sequence, or detect, treat, or prevent cancer, to a similar extent, the same extent, or to a higher extent, as compared to the parent TCR. In reference to the parent TCR, the functional portion can comprise, for instance, about 10%, about 25%, about 30%, about 50%, about 68%, about 80%, about 90%, about 95%, or more, of the parent TCR.

[0093] The antigen-binding portion can comprise an antigen-binding portion of either or both of the α and β chains of the TCR, such as a portion comprising one or more of the complementarity determining region (CDR)1, CDR2, and CDR3 of the variable region(s) of the α chain and/or β chain of the TCR. In an embodiment of the invention, the antigen-binding portion can comprise the amino acid sequence of the CDR1 of the α chain (CDR1 α), the CDR2 of the α chain (CDR2 α), the CDR3 of the α chain (CDR3 α), the CDR1 of the β chain (CDR1 β), the CDR2 of the β chain (CDR2 β), the CDR3 of the β chain (CDR3 β), or any combination thereof. Preferably, the antigen-binding portion comprises the amino acid sequences of CDR1 α , CDR2 α , and CDR3 α ; the amino acid sequences of CDR1 β , CDR2 β , and CDR3 β ; or the amino acid sequences of all of CDR1 α , CDR2 α , CDR3 α , CDR1 β , CDR2 β , and CDR3 β of the TCR.

[0094] In an embodiment of the invention, the antigen-binding portion can comprise, for instance, the variable region of the TCR comprising a combination of the CDR regions set forth above. In this regard, the antigen-binding portion can comprise the amino acid sequence of the variable region of the α chain (V α), the amino acid sequence of the variable region of the β chain (V β), or the amino acid sequences of both of the V α and V β of the TCR.

[0095] In an embodiment of the invention, the antigen-binding portion may comprise a combination of a variable region and a constant region. In this regard, the antigen-binding portion can comprise the entire length of the α or β chain, or both of the α and β chains, of the TCR.

[0096] Isolating the nucleotide sequence that encodes the TCR, or the antigen-binding portion thereof, from the selected T cells may be carried out in any suitable manner known in the art. For example, the method may comprise isolating RNA from the selected T cells and sequencing the TCR, or the antigen-binding portion thereof, using established molecular cloning techniques and reagents such as, for example, 5' Rapid Amplification of cDNA Ends (RACE) polymerase chain reaction (PCR) using TCR- α and - β chain constant primers.

Alternatively or additionally, techniques and systems useful for isolating a TCR nucleic acid sequence may include, for example, single-cell reverse transcription polymerase chain reaction (RT-PCR), bioinformatic reconstruction, limiting dilution cloning, the FLUIDIGM system (Fluidigm Corporation, South San Francisco, CA), deep sequencing of TCR α and TCR β chains with frequency pairing, PAIRSEQ method of identifying TCR α and β chain pairs from Adaptive Biotechnologies (Seattle, WA), and combinations thereof.

[0097] In an embodiment of the invention, the method may comprise cloning the nucleotide sequence that encodes the TCR, or the antigen-binding portion thereof, into a recombinant expression vector using established molecular cloning techniques as described in, e.g., Green et al. (Eds.), *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press; 4th Ed. (2012). For purposes herein, the term "recombinant expression vector" means a genetically-modified oligonucleotide or polynucleotide construct that permits the expression of an mRNA, protein, polypeptide, or peptide by a host cell, when the construct comprises a nucleotide sequence encoding the mRNA, protein, polypeptide, or peptide, and the vector is contacted with the cell under conditions sufficient to have the mRNA, protein, polypeptide, or peptide expressed within the cell. The vectors may not be naturally-occurring as a whole. However, parts of the vectors can be naturally-occurring. The recombinant expression vectors can comprise any type of nucleotides, including, but not limited to DNA (e.g., complementary DNA (cDNA)) and RNA, which can be single-stranded or double-stranded, synthesized or obtained in part from natural sources, and which can contain natural, non-natural or altered nucleotides. The recombinant expression vectors can comprise naturally-occurring, non-naturally-occurring internucleotide linkages, or both types

of linkages. Preferably, the non-naturally occurring or altered nucleotides or internucleotide linkages does not hinder the transcription or replication of the vector.

[0098] The recombinant expression vector can be any suitable recombinant expression vector, and can be used to transform or transfect any suitable host cell. Suitable vectors include those designed for propagation and expansion or for expression or both, such as plasmids and viruses. The vector can be selected from the group consisting of transposon/transposase, the pUC series (Fermentas Life Sciences), the pBluescript series (Stratagene, LaJolla, CA), the pET series (Novagen, Madison, WI), the pGEX series (Pharmacia Biotech, Uppsala, Sweden), and the pEX series (Clontech, Palo Alto, CA). Bacteriophage vectors, such as λ GT10, λ GT11, λ ZapII (Stratagene), λ EMBL4, and λ NM1149, also can be used. Examples of plant expression vectors include pBI01, pBI101.2, pBI101.3, pBI121 and pBIN19 (Clontech). Examples of animal expression vectors include pEUK-CI, pMAM and pMAMneo (Clontech). Preferably, the recombinant expression vector is a viral vector, e.g., a retroviral vector.

[0099] The TCR, or the antigen-binding portion thereof, isolated by the inventive methods may be useful for preparing cells for adoptive cell therapies. In this regard, an embodiment of the invention provides a method of preparing a population of cells that express a TCR, or an antigen-binding portion thereof, having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising isolating a TCR, or an antigen-binding portion thereof, as described herein with respect to other aspects of the invention, and introducing the nucleotide sequence encoding the isolated TCR, or the antigen-binding portion thereof, into host cells to obtain cells that express the TCR, or the antigen-binding portion thereof.

[0100] Introducing the nucleotide sequence (e.g., a recombinant expression vector) encoding the isolated TCR, or the antigen-binding portion thereof, into host cells may be carried out in any of a variety of different ways known in the art as described in, e.g., Green et al. *supra*. Non-limiting examples of techniques that are useful for introducing a nucleotide sequence into host cells include transformation, transduction, transfection, transposition, and electroporation.

[0101] The host cell into which the nucleotide sequence encoding the TCR, or antigen binding portion thereof, is introduced may be any type of cell that can contain the recombinant expression vector. The host cell can be a eukaryotic cell, e.g., plant, animal, fungi, or algae, or can be a prokaryotic cell, e.g., bacteria or protozoa. The host cell can be a

cultured cell or a primary cell, i.e., isolated directly from an organism, e.g., a human. The host cell can be an adherent cell or a suspended cell, i.e., a cell that grows in suspension. Suitable host cells are known in the art and include, for instance, DH5 α E. coli cells, Chinese hamster ovarian cells, monkey VERO cells, COS cells, HEK293 cells, and the like. For purposes of amplifying or replicating the recombinant expression vector, the host cell is preferably a prokaryotic cell, e.g., a DH5 α cell. For purposes of producing the TCR, or antigen binding portion thereof, the host cell is preferably a mammalian cell. Most preferably, the host cell is a human cell. While the host cell can be of any cell type, can originate from any type of tissue, and can be of any developmental stage, the host cell preferably is a PBL or a PBMC. More preferably, the host cell is a T cell.

[0102] In an embodiment of the invention, the PBMC include T cells. The T cells may be any type of T cell. Without being bound to a particular theory or mechanism, it is believed that less differentiated, “younger” T cells may be associated with any one or more of greater *in vivo* persistence, proliferation, and antitumor activity as compared to more differentiated, “older” T cells. Accordingly, the inventive methods may, advantageously, identify and isolate a TCR, or an antigen-binding portion thereof, that has antigenic specificity for the mutated p53 amino acid sequence and introduce the TCR, or an antigen-binding portion thereof, into “younger” T cells that may provide any one or more of greater *in vivo* persistence, proliferation, and antitumor activity as compared to “older” T cells (e.g., effector cells in a patient’s tumor).

[0103] In an embodiment of the invention, the inventive methods identify and isolate TCRs, or the antigen-binding portions thereof, that have antigenic specificity against a mutated p53 amino acid sequence that is encoded by a recurrent (also referred to as “hot-spot”) cancer-specific p53 mutation. In this regard, the method may comprise introducing the nucleotide sequence encoding the isolated TCR, or the antigen-binding portion thereof, into host cells that are allogeneic to the patient. For example, the method may comprise introducing the nucleotide sequence encoding the isolated TCR, or the antigen-binding portion thereof, into the host cells from another patient whose tumors express the same p53 mutation in the context of the same MHC molecule.

[0104] In an embodiment of the invention, the method further comprises expanding the numbers of host cells that express the TCR, or the antigen-binding portion thereof. The numbers of host cells may be expanded, for example, as described herein with respect to other aspects of the invention. In this regard, the inventive methods may, advantageously,

generate a large number of T cells having antigenic specificity for the mutated p53 amino acid sequence.

[0105] Another embodiment of the invention provides an isolated population of cells prepared according to any of the methods described herein with respect to other aspects of the invention. The population of cells can be a heterogeneous population comprising the T cells having antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation in addition to at least one other cell, e.g., a PBMC which does not have antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation, or a cell other than a T cell, e.g., a B cell, a macrophage, a neutrophil, an erythrocyte, a hepatocyte, an endothelial cell, an epithelial cells, a muscle cell, a brain cell, etc. Alternatively, the population of cells can be a substantially homogeneous population, in which the population comprises mainly of (e.g., consisting essentially of) T cells having antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation. The population also can be a clonal population of cells, in which all cells of the population are clones of a single T cell, such that all cells of the population have antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation. In one embodiment of the invention, the population of cells is a clonal population comprising T cell having antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation, as described herein. In an embodiment of the invention, about 1% to about 100%, for example, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%, or a range defined by any two of the foregoing values, of the population of cells comprises T cells that have antigenic specificity for the mutated p53 amino acid sequence. Without being bound to a particular theory or mechanism, it is believed that populations of cells that comprise a high proportion of T cells that have antigenic specificity for the mutated p53 amino acid sequence advantageously may have a lower proportion of irrelevant cells that may hinder the function of the T cell, e.g., the ability of the T cell to target the destruction of cancer cells and/or treat or prevent cancer.

[0106] The inventive populations of cells can be formulated into a composition, such as a pharmaceutical composition. In this regard, the invention provides a pharmaceutical composition comprising any of the inventive populations of cells and a pharmaceutically

acceptable carrier. The inventive pharmaceutical composition can comprise an inventive population of cells in combination with another pharmaceutically active agent(s) or drug(s), such as a chemotherapeutic agents, e.g., asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, vincristine, etc.

[0107] Preferably, the carrier is a pharmaceutically acceptable carrier. With respect to pharmaceutical compositions, the carrier can be any of those conventionally used for the particular inventive population of cells under consideration. Such pharmaceutically acceptable carriers are well-known to those skilled in the art and are readily available to the public. It is preferred that the pharmaceutically acceptable carrier be one which has no detrimental side effects or toxicity under the conditions of use.

[0108] The choice of carrier will be determined in part by the particular inventive population of cells, as well as by the particular method used to administer the inventive population of cells. Accordingly, there are a variety of suitable formulations of the pharmaceutical composition of the invention. Suitable formulations may include any of those for parenteral, subcutaneous, intravenous, intramuscular, intraarterial, intratumoral, intrathecal, or interperitoneal administration. More than one route can be used to administer the inventive population of cells, and in certain instances, a particular route can provide a more immediate and more effective response than another route.

[0109] Preferably, the inventive population of cells is administered by injection, e.g., intravenously. When the inventive population of cells is to be administered, the pharmaceutically acceptable carrier for the cells for injection may include any isotonic carrier such as, for example, normal saline (about 0.90% w/v of NaCl in water, about 300 mOsm/L NaCl in water, or about 9.0 g NaCl per liter of water), NORMOSOL R electrolyte solution (Abbott, Chicago, IL), PLASMA-LYTE A (Baxter, Deerfield, IL), about 5% dextrose in water, or Ringer's lactate. In an embodiment, the pharmaceutically acceptable carrier is supplemented with human serum albumin.

[0110] It is contemplated that the inventive populations of cells and pharmaceutical compositions can be used in methods of treating or preventing cancer. Without being bound to a particular theory or mechanism, the inventive T cells are believed to bind specifically to a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, such that a TCR expressed by the cell is able to mediate an immune response against a target cell expressing the mutated p53 amino acid sequence. In this regard, an embodiment of the

invention provides a method of treating or preventing cancer in a mammal, comprising administering to the mammal any of the pharmaceutical compositions or populations of cells described herein, in an amount effective to treat or prevent cancer in the mammal.

[0111] The terms "treat," and "prevent" as well as words stemming therefrom, as used herein, do not necessarily imply 100% or complete treatment or prevention. Rather, there are varying degrees of treatment or prevention of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the inventive methods can provide any amount of any level of treatment or prevention of cancer in a mammal.

Furthermore, the treatment or prevention provided by the inventive method can include treatment or prevention of one or more conditions or symptoms of the cancer being treated or prevented. For example, treatment or prevention can include promoting the regression of a tumor. Also, for purposes herein, "prevention" can encompass delaying the onset of the cancer, or a symptom or condition thereof.

[0112] For purposes of the invention, the amount or dose of the inventive population of cells or pharmaceutical composition administered (e.g., numbers of cells when the inventive population of cells is administered) should be sufficient to effect, e.g., a therapeutic or prophylactic response, in the mammal over a reasonable time frame. For example, the dose of the inventive population of cells or pharmaceutical composition should be sufficient to bind to a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, or detect, treat or prevent cancer in a period of from about 2 hours or longer, e.g., 12 to 24 or more hours, from the time of administration. In certain embodiments, the time period could be even longer. The dose will be determined by the efficacy of the particular inventive population of cells or pharmaceutical composition administered and the condition of the mammal (e.g., human), as well as the body weight of the mammal (e.g., human) to be treated.

[0113] Many assays for determining an administered dose are known in the art. For purposes of the invention, an assay, which comprises comparing the extent to which target cells are lysed or IFN- γ is secreted by T cells upon administration of a given dose of such T cells to a mammal among a set of mammals of which is each given a different dose of the T cells, could be used to determine a starting dose to be administered to a mammal. The extent to which target cells are lysed or IFN- γ is secreted upon administration of a certain dose can be assayed by methods known in the art.

[0114] The dose of the inventive population of cells or pharmaceutical composition also will be determined by the existence, nature and extent of any adverse side effects that might

accompany the administration of a particular inventive population of cells or pharmaceutical composition. Typically, the attending physician will decide the dosage of the inventive population of cells or pharmaceutical composition with which to treat each individual patient, taking into consideration a variety of factors, such as age, body weight, general health, diet, sex, inventive population of cells or pharmaceutical composition to be administered, route of administration, and the severity of the condition being treated.

[0115] In an embodiment in which the inventive population of cells is to be administered, the number of cells administered per infusion may vary, for example, in the range of one million to 100 billion cells; however, amounts below or above this exemplary range are within the scope of the invention. For example, the daily dose of inventive host cells can be about 1 million to about 150 billion cells (e.g., about 5 million cells, about 25 million cells, about 500 million cells, about 1 billion cells, about 5 billion cells, about 20 billion cells, about 30 billion cells, about 40 billion cells, about 60 billion cells, about 80 billion cells, about 100 billion cells, about 120 billion cells, about 130 billion cells, about 150 billion cells, or a range defined by any two of the foregoing values), preferably about 10 million to about 130 billion cells (e.g., about 20 million cells, about 30 million cells, about 40 million cells, about 60 million cells, about 70 million cells, about 80 million cells, about 90 million cells, about 10 billion cells, about 25 billion cells, about 50 billion cells, about 75 billion cells, about 90 billion cells, about 100 billion cells, about 110 billion cells, about 120 billion cells, about 130 billion cells, or a range defined by any two of the foregoing values), more preferably about 100 million cells to about 130 billion cells (e.g., about 120 million cells, about 250 million cells, about 350 million cells, about 450 million cells, about 650 million cells, about 800 million cells, about 900 million cells, about 3 billion cells, about 30 billion cells, about 45 billion cells, about 50 billion cells, about 75 billion cells, about 90 billion cells, about 100 billion cells, about 110 billion cells, about 120 billion cells, about 130 billion cells, or a range defined by any two of the foregoing values).

[0116] For purposes of the inventive methods, wherein populations of cells are administered, the cells can be cells that are allogeneic or autologous to the mammal. Preferably, the cells are autologous to the mammal.

[0117] Another embodiment of the invention provides any of the isolated population of cells or pharmaceutical compositions described herein for use in treating or preventing cancer in a mammal.

[0118] With respect to the inventive methods, the cancer can be any cancer, including any of acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vagina, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, uterine cervical cancer, gastrointestinal carcinoid tumor, glioma, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, cancer of the oropharynx, ovarian cancer, cancer of the penis, pancreatic cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, cancer of the uterus, ureter cancer, and urinary bladder cancer. In a preferred embodiment, the cancer is a cancer which expresses mutated p53. The cancer may express p53 with a mutation at one or more of positions 175, 220, 245, 248, 249, 273, or 282 of SEQ ID NO: 1. The cancer may express p53 with one or more of the following human p53 mutations: R175H, Y220C, G245D, G245S, R248L, R248Q, R248W, R249S, R273H, R273C, R273L, or R282W. Preferably, the cancer is an epithelial cancer or cholangiocarcinoma, melanoma, colon cancer, rectal cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), glioblastoma, uterine cervical cancer, head and neck cancer, breast cancer, pancreatic cancer, or bladder cancer.

[0119] The mammal referred to in the inventive methods can be any mammal. As used herein, the term "mammal" refers to any mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits. It is preferred that the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs). Preferably, the mammals are from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perssodactyla, including Equines (horses). Preferably, the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids (humans and apes). A more preferred mammal is the human.

[0120] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.

EXAMPLES

[0121] The amino acid sequences set forth in Tables 1-3 were employed in the experiments described in the following Examples.

TABLE 1

SEQ ID NO:	Name	Sequence
2	LP-p53-R175H-MUT	YKQSQHMTEVVR <u>H</u> CPHHERCSDSDG
3	LP-p53-R273H-MUT	SGNLLGRNSFEV <u>H</u> VCACPGRDRRTE
4	LP-p53-R248L-MUT	YMCNSSCMGGMN <u>L</u> RPILTIITLEDSS
5	LP-p53-R282W-MUT	FEVRVCACPGRD <u>W</u> RTEENLRKKGE
6	LP-p53-R273C-MUT	SGNLLGRNSFEV <u>C</u> VCACPGRDRRTE
7	LP-p53-G245S-MUT	HNYMCNSSCMG <u>S</u> MNRRPILTIITL
8	LP-p53-R248Q-MUT	YMCNSSCMGGMN <u>Q</u> RPILTIITLEDSS
9	LP-p53-G245D-MUT	HNYMCNSSCMG <u>D</u> MNRRPILTIITL
10	LP-p53-R273L-MUT	SGNLLGRNSFEV <u>L</u> VCACPGRDRRTE
11	LP-p53-R248W-MUT	YMCNSSCMGGMN <u>W</u> RPILTIITLEDSS
12	LP-p53-Y220C-MUT	DRNTFRHSVVP <u>C</u> EPPEVGSDCTTI
13	LP-p53-R249S-MUT	MCNSSCMGGMNR <u>S</u> PILTIITLEDSS

[0122] The wild-type versions of the peptides of Table 1 are set forth in Table 2.

TABLE 2

SEQ ID NO:	Name	Sequence
15	LP-p53-R175-WT	YKQSQHMTEVVR <u>R</u> CPHHERCSDSDG
16	LP-p53-R273-WT	SGNLLGRNSFEV <u>R</u> VCACPGRDRRTE
17	LP-p53-R248-WT	YMCNSSCMGGMN <u>R</u> RPILTIITLEDSS
18	LP-p53-R282-WT	FEVRVCACPGRD <u>R</u> RTEENLRKKGE
19	LP-p53-G245-WT	HNYMCNSSCMG <u>G</u> MNRRPILTIITL

SEQ ID NO:	Name	Sequence
20	LP-p53-Y220-WT	DRNTFRHSVVVP <u>Y</u> EPPEVGS DCTTI
21	LP-p53-R249-WT	MCNSSCMGGMNR <u>R</u> PILTIITLEDSS

TABLE 3

SEQ ID NO:	Name	Sequence
14	TMG-p53-MUT	YKQSQHMTEVVR <u>H</u> CPHHERCSDSDGSGNLLGRNSFEV <u>H</u> VACAPGRDRRTEYMCNSSCMGGM <u>N</u> L <u>R</u> PILTIITLEDSE EVRVCACPGRD <u>W</u> RTEENLRKKGESGNLLGRNSFEV <u>C</u> VCACPGRDRRTEHYNYMCNSSCMG <u>S</u> MNRRPILTIITLY MCNSSCMGGM <u>N</u> <u>Q</u> RPILTIITLEDSEHYNYMCNSSCMG <u>D</u> MNRRPILTIITLSGNLLGRNSFEV <u>L</u> VACAPGRDRRTEYM CNSSCMGGM <u>N</u> <u>W</u> RPILTIITLEDSEDRNTFRHSVVVP <u>C</u> EP EVGSDCTTIMCNSSCMGGMNR <u>S</u> PILTIITLEDSS
22	TMG-p53-WT	YKQSQHMTEVVR <u>R</u> CPHHERCSDSDGSGNLLGRNSFEV <u>R</u> VACAPGRDRRTEYMCNSSCMGGM <u>N</u> <u>R</u> PILTIITLEDSE EVRVCACPGRD <u>R</u> RTEENLRKKGESGNLLGRNSFEV <u>R</u> V CACPGRDRRTEHYNYMCNSSCMG <u>G</u> MNRRPILTIITLYM CNSSCMGGM <u>N</u> <u>R</u> RPILTIITLEDSEHYNYMCNSSCMG <u>G</u> MN RRPILTIITLSGNLLGRNSFEV <u>R</u> VACAPGRDRRTEYMCNS SCMGGM <u>N</u> <u>R</u> RPILTIITLEDSEDRNTFRHSVVVP <u>Y</u> EPPEVGS DCTTIMCNSSCMGGMNR <u>R</u> PILTIITLEDSS

EXAMPLE 1

[0123] This example demonstrates the identification of anti-mutated p53 T cells in Patient 4141 by co-culturing autologous APCs induced to express mutated p53 within autologous T cells (“p53 hotspot mutation universal screening”). This example also demonstrates the isolation and specific reactivity of a TCR from patient 4141.

[0124] Experiments were carried out as described for Figures 1 and 45-48 for Patient 4141. TIL fragment F12 and infusion bag TIL (Rx1) from patient 4141 and p53-R175H-specific TCR or mock transduced T cells from patient 4196 were used as effectors. Co-cultures with T cell effectors and HLA-A*02:01 APCs (autologous to patient 4141) were either (1) electroporated with TMGs composed of irrelevant, WT p53, or mutated p53 sequences or (2) pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25 amino

acid peptides composed of WT p53-R175 sequence or mutated p53-R175H sequence. T cells only (no target) was negative control and PMA and Iono was positive control (lattice bars). Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 1.

[0125] Autologous APCs were transfected with TMG encoding irrelevant mutations, WT p53 sequence, or mutated p53 sequence including R175H. Media alone and PMA and ionomycin were negative and positive controls, respectively. The following day, TIL from patient 4141 (fragment culture 12) were co-cultured overnight at 37 °C with TMG-transfected APCs. Secretion of IFN- γ was evaluated by ELISPOT. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes \rightarrow living cells (PI negative) \rightarrow CD3+ (T cells) \rightarrow CD4-CD8+. The results are shown in Figure 45.

[0126] Cos7 cells (2.5×10^4 per well) were plated on wells of flat-bottom 96 well plates. The following day, cells were co-transfected with individual HLA alleles from patient 4141 and either no extra gene, WT TP53 TMG, or mutated TP53 TMG containing the p53-R175H sequence. TIL with specificity to p53-R175H from Patient 4141 (fragment culture 12) were co-cultured the following day with transfected Cos7 cells and were incubated overnight at 37 °C. Secretion of IFN- γ was evaluated by ELISPOT. The results are shown in Figure 46.

[0127] T cells expressing mock (no TCR) or 4141-TCR1a2 were co-cultured with T2 tumor cells (expressing HLA-A*02:01). T2 cells were pulsed for 2 hours at 37 °C with peptide vehicle (DMSO) or purified (>95% by HPLC) peptides composed of WT p53-R175 peptide HMTEVVRRRC (SEQ ID NO: 532) or mutated p53-R175H peptide HMTEVVRRHC (SEQ ID NO: 530). Media alone and PMA and Ionomycin were negative and positive controls, respectively. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated by ELISA. The results are shown in Figure 47.

[0128] T cells expressing 4141-TCR1a2 were co-cultured overnight at 37 °C with Saos2 cells (p53-NUL and HLA-A*02:01+), which were either unmanipulated or made to overexpress full length p53-R175H protein. Inhibitors of secretion (monensin and brefeldin A) were added to co-cultures to trap cytokines within T cells. After 6 hours of co-culture, cells were fixed and permeabilized then stained for IL-2, CD107a, IFN- γ and tumor necrosis factor-alpha (TNF α). Flow cytometry was used to analyze co-cultures based on a lymphocyte gate. The results are shown in Figure 48.

[0129] The sequence of TCR **4141-TCR1a2**, which was isolated from Patient 4141, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha

(SEQ ID NO: 467), the second underlined region is the CDR2alpha (SEQ ID NO: 468), the third underlined region is the CDR3alpha (SEQ ID NO: 469), the fourth underlined region is the CDR1beta (SEQ ID NO: 470), the fifth underlined region is the CDR2beta (SEQ ID NO: 471), and the sixth underlined region is the CDR3beta (SEQ ID NO: 472). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 473) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 474) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 475) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 476) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0130] Cancer reactive T cells were identified as described below. The TCR was isolated as described below.

TCR name: 4141-TCR1a2

Recognition of p53 mutation: R175H

Screening method: p53 "hotspot" mutation universal screening

Co-culture to identify TCR: Co-culture 4141 infusion bag TIL with p53mutTMG and sorted CD8+41BB+ T cells

Method to identify TCR: single-cell RT-PCR then TA TOPO cloning kit (Thermo Fisher Scientific, Waltham, MA) for alpha chain

TCR orientation: alpha-beta

Expression vector: SB transposon

MASIRAVFIFLWLQLDLVNGENVEQHPSTLSVQEGDSAVIKCTYSDSASNYFPWYKQ
 ELGKGPQLIIDIRSNVGEKKDQRIAVTLNKTAKHFS~~HL~~HITETQPEDSAVYFCAASKSAI
 M~~V~~V~~L~~Q~~T~~SS~~S~~LELALCLLSSQVNIQ~~N~~PEPAVYQLKDPRS~~Q~~DSTLCLFTDFDSQINVPKTME
 SGTFITDKCVLDMKAMD~~S~~KSN~~G~~AIAWSN~~Q~~T~~S~~FT~~C~~Q~~D~~IFKETNATYPSSDVPCDATL~~T~~EK~~S~~F
 E~~T~~DMN~~L~~N~~F~~Q~~N~~LLVIVLRILLK~~V~~AGFNLLM~~T~~RLWSSRAK~~R~~SGSGATNFSLLKQAGDV
EENPGPMHPQLLGYVVLCLLGAGPLEAQVTQNP~~R~~YLITVTGKKLTVTCSQNM~~N~~HEY
 MSWYRQDPGLGLRQIYY~~S~~M~~N~~VEVTDKGDVPEGYK~~V~~SRKEKRN~~F~~PLILESPSPNQ~~T~~SL
 YFCASSIQQ~~G~~ADTQYFGPGTR~~L~~TVLEDLRNVTPPKV~~S~~LFEP~~S~~KA~~E~~IANKQKATLVCLARG
 FFPDHVELSW~~V~~NGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNP~~R~~NHFRCQV
 QFHGLSEEDKWPEGSPK~~P~~VTONISAEAWGRADCGITSASYQ~~Q~~GVLSATILYEILLGKATLYA
 VLVSTLVVMAMV~~K~~RKNS (SEQ ID NO: 587)

[0131] The statistics for 4141-TCR1a2 from patient 4141 are set forth in Table 4 below.

TABLE 4

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	Unknown (TA TOPO cloning)	Not applicable
CDR3beta	58	60.4%

EXAMPLE 2

[0132] This example demonstrates the identification of anti-mutated p53 T cells in Patient 4130 by co-culturing autologous APCs induced to express mutated p53 within autologous T cells (“p53 hotspot mutation universal screening”).

[0133] Experiments were carried out as described for Figure 2 for Patient 4130. TIL fragments (F14, F20 and F24) from patient 4130 were co-cultured with autologous APCs (1) electroporated with TMGs composed of irrelevant, WT p53 or mutated p53 sequences or (2) pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R273 sequence or mutated p53-R273H sequence. Co-cultures were performed overnight at 37 °C. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes → living cells (PI negative) → CD3+ (T cells). The results are shown in Figure 2.

EXAMPLE 3

[0134] This example demonstrates the identification of anti-mutated p53 T cells in Patient 4259 by co-culturing autologous APCs induced to express mutated p53 within autologous T cells (“p53 hotspot mutation universal screening”). This example also demonstrates the isolation and specific reactivity of a TCR isolated from patient 4259.

[0135] Experiments were carried out as described for Figures 3-8 and 49-53 for Patient 4259. TIL fragments (n=18) from patient 4259 were co-cultured with autologous APCs electroporated with TMG composed of irrelevant, WT p53 or mutated p53 sequences. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 3. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes → living cells (PI negative) → CD3+ (T cells). The results are shown in Figures 4-5.

[0136] TIL fragments (n=18) from patient 4259 were co-cultured with autologous APCs pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-Y220 sequence or mutated p53-Y220C sequence. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 6. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes \rightarrow living cells (PI negative) \rightarrow CD3+ (T cells). The results are shown in Figures 7-8.

[0137] TIL fragment culture (no. 6) from patient 4259 was co-cultured with autologous APCs either (1) electroporated with TMG composed of irrelevant, WT p53, or mutated p53 sequence or (2) pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-Y220 sequence or mutated p53-Y220C sequence. Co-cultures were performed overnight at 37 °C. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes \rightarrow living cells (PI negative) \rightarrow CD3+ (T cells). The results are shown in Figure 49.

[0138] Autologous APCs were pulsed with decreasing concentrations of 25-amino acid peptides corresponding to the WT p53-Y220 or mutated p53-Y220C sequence for 2 hours at 37 °C. TIL fragment culture (no. 6) from patient 4259 was co-cultured with peptide-pulsed APCs. Expression of 4-1BB was assayed by flow cytometry after gating lymphocytes \rightarrow living cells (PI negative) \rightarrow CD3+ (T cells). The results are shown in Figure 50.

[0139] Autologous antigen presenting cells were pulsed with DMSO, WT p53-Y220 peptide RNTFRHSVVPYE (SEQ ID NO: 533) or mutated p53-Y220C peptide RNTFRHSVVPCE (SEQ ID NO: 534) for 2 hours at 37 °C. Excess peptide was washed away. TIL from patient 4259 (fragment culture 6) with specificity to p53-Y220C was co-cultured overnight at 37 °C with peptide-pulsed APCs. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes \rightarrow living cells (PI negative) \rightarrow CD3+ (T cells). The results are shown in Figure 51.

[0140] Cos7 cells (2.5×10^4 per well) were plated on wells of flat-bottom 96 well plates. The following day, cells were co-transfected with individual HLA alleles from patient 4259. The next day, DMSO or the p53-Y220C peptide RNTFRHSVVPCE (SEQ ID NO: 534) were pulsed for 2 hours on transfected Cos7 cells. Excess peptide was washed away. TIL fragment culture no.6 from Patient 4259 was added (10^5 cells/well). Co-cultures were incubated overnight at 37 °C. Expression of 4-1BB was assayed by flow cytometry after

gating lymphocytes → live → CD3+ (T cells) → CD8-CD4+. The results are shown in Figure 52.

[0141] APCs autologous to Patient 4259 were pulsed with 25-amino acid peptides corresponding to the WT p53-Y220 or mutated p53-Y220C sequence for 2 hours at 37 °C. Excess peptide was washed away. T cells expressing 4259-F6-TCR were co-cultured overnight at 37 °C with peptide-pulsed APCs. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes → living cells (PI negative) → CD3+ (T cells). The introduced TCR was measured by mouse TCRbeta (mTCR). The results are shown in Table 5.

TABLE 5

	WT p53-Y220	Mut p53-Y220C
4-1BB+/mTCR+	0.27	5.22
4-1BB-/mTCR-	68.5	73.7
4-1BB+/mTCR-	0.18	1.59
4-1BB-/mTCR+	31.0	19.5

[0142] A tumor cell (TC) line was established from a xenografted tumor fragment resected from Patient 4259 and then serially passaged through immunocompromised mice (TC#4259). TC#4259 was co-cultured with T cells (10^5) expressing mock (no TCR) or p53-Y220C-specific TCR (4259-F6-TCR) overnight at 37 °C. The TC#4259 cells were either incubated with nothing, W6/32 pan-HLA Class-I specific blocking antibody, IVA12 pan-HLA Class-II specific blocking antibody or mutated p53-Y220C peptide RNTFRHSVVPCE (SEQ ID NO: 534) for 2 hours at 37 °C. The antibodies were kept in the co-culture at 5 µg/mL final concentration. The peptide was incubated at 10 µg/mL and excess peptide was washed after incubation. Media alone (no TC) and PMA and Ionomycin were negative and positive controls, respectively. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes → living cells (PI negative) → CD3+ (T cells). The results are shown in Figure 53.

[0143] The sequence of TCR **4259-F6-TCR**, which was isolated from Patient 4259, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 477), the second underlined region is the CDR2alpha (SEQ ID NO: 478), the third underlined region is the CDR3alpha (SEQ ID NO: 479), the fourth underlined region is

the CDR1beta (SEQ ID NO: 480), the fifth underlined region is the CDR2beta (SEQ ID NO: 481), and the sixth underlined region is the CDR3beta (SEQ ID NO: 482). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 483) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 484) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 485) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 486) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0144] Cancer reactive T cells were identified as described below. The TCR was isolated as described below.

TCR name: 4259-F6-TCR

Recognition of p53 mutation: Y220C

Screening method: p53 "hotspot" mutation universal screening

Co-culture to identify TCR: Co-culture 4259-F6 with p53-Y220C peptide and sorted CD4+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 81.1% (observed 36 times of 44 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MASLRVLLVILWLQLSWVWSQQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFW
 YRQYSGKSP~~ELIMFI~~YSNGDKEDGRFTAQLNKASQYVSLIRDSQPSDSATYLCAWN
SGGSNYKLTFGKGTLLTVNPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMES
GTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFE
 TDMNLNFQNLLVIVLRILLKVAGFNLLMTLRLWSSRAKRSGSGATNFSLLKQAGDVE
 ENPGPMHLGLLCCGAFSLLWAGPVNAGVTQTPKFRVLKTGQSMTLLCAQDMNHEY
 MYWYRQDPGMGLRLIHYSVGEGTTAKGEVPDGYNVSRLKKQNFLLGLESAAPSQTS
 VYFCASSYSQAWGPQHFGDGTRLSILEDLRNVTPPKVSLFEPSKAEIANKQKATLVCL
 ARGFFPDHVELSWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFR
 CQVQFHGLSEEDKWPEGSPKPVTONISAEAWGRADCGITSASYQQGVLSATILYEILLGKA
 TLYAVLVSTLVVMAMVKRKNS (SEQ ID NO: 588)

[0145] The statistics for **4259-F6-TCR** from patient 4259 are set forth in Table 6 below.

TABLE 6

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	41	42.7%
CDR3beta	47	49.0%
4259-F6-TCR pairs	36	37.5%
Total paired TCRs	44	45.8%

EXAMPLE 4

[0146] This example demonstrates the identification of anti-mutated p53 T cells in Patient 4127 by co-culturing autologous APCs induced to express mutated p53 within autologous T cells (“p53 hotspot mutation universal screening”).

[0147] Experiments were carried out as described for Figures 9-10 for Patient 4127. TIL from patient 4127 were co-cultured with allogeneic (DRB3*01:01:01 or DRB3*02:02:01) APCs which were (1) electroporated with TMGs composed of irrelevant, WT p53 or mutated p53 sequences or (2) pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-G245 sequence or mutated p53-G245S sequence. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 9.

[0148] T cells expressing the 4127-TCR1 specific for p53-G245S were co-cultured with allogeneic (DRB3*01:01:01 or DRB3*02:02:01) APCs which were (1) electroporated with TMGs composed of irrelevant, WT p53 or mutated p53 sequences or (2) pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-G245 sequence or mutated p53-G245S sequence. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 10.

EXAMPLE 5

[0149] T cells from 27 patients were screened by (i) inducing autologous antigen presenting cells (APCs) of a patient to present at least one mutated p53 amino acid sequence; (ii) co-culturing autologous T cells of the patient with the autologous APCs that present the mutated p53 amino acid sequence; and (iii) selecting the autologous T cells that (a) were co-cultured with the autologous APCs that present the mutated p53 amino acid sequence. A

summary of responses to p53 “hostpot” mutations by T cells using the screening method is provided in Table 7.

TABLE 7

Mutation	# Pt	% Pt	# tested	# reactive	% reactive of screened
R175H	7	19%	6	4	66.7%
Y220C	3	8%	3	2	66.7%
G245D	1	3%	1	0	0.0%
G245S	2	6%	1	1	100.0%
R248L	0	0%	0	0	Not applicable
R248Q	6	17%	6	3	50.0%
R248W	6	17%	5	3	60.0%
R249S	0	0%	0	0	Not applicable
R273C	2	6%	1	0	0.0%
R273H	5	14%	5	1	20.0%
R273L	0	0%	0	0	Not applicable
R282W	4	11%	3	2	66.7%
Total	36	100%	31	16	51.6%

EXAMPLE 6

[0150] This example demonstrates the identification of anti-mutated p53 T cells in Patient 4273 by co-culturing autologous APCs induced to express mutated p53 within autologous T cells (“p53 hotspot mutation universal screening”). This example also demonstrates the isolation of two anti-mutated p53 TCRs from patient 4273.

[0151] Experiments were carried out as described for Figures 11-14 and 33-37 for Patient 4273. TIL fragments (F1-F24, n=24) from patient 4273 were co-cultured with autologous APCs electroporated with TMG composed of irrelevant, WT p53 or mutated p53 sequence. Co-cultures were performed overnight at 37 °C. Secretion of IFN-γ was evaluated using ELISPOT assay. The results are shown in Figure 11. Expression of 4-1BB was evaluated by

flow cytometry after gating for lymphocytes → living cells (PI negative) → CD3+ (T cells). The results are shown in Figure 12.

[0152] TIL fragments (F1-F24, n=24) from patient 4273 were co-cultured with autologous APCs pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-R248 sequence or mutated p53-R248W sequence. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 13. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes → living cells (PI negative) → CD3+ (T cells). The results are shown in Figure 14.

[0153] For patient 4273, F15 was the most reactive fragment and the responses by F15 to the LP and TMG were comparable and primarily by CD4 T cells. So 4273-F15 was co-cultured with APCs pulsed with the R248W LP, and the following day we sorted CD4+41BB+ T cells as single cells into wells a 96 well PCR plate at one cell per well. The PCR plate has an RT-PCR solution in each well, which amplifies the TCR alpha and beta CDR3 regions in the same solution. The wells of the plate are then split into two 96 well PCR plates and a second PCR round is performed to amplify either the CDR3 alpha or the CDR3 beta as separate reactions. The PCR products from each well (total of 192 PCR products mapped to each well – alpha or beta) are sequenced by Sanger sequencing. The nucleotide sequence is inputted into IMGT/V-QUEST (imgt.org/IMGT_vquest/vquest?livret=0&Option=humanTcR), IgBlast (ncbi.nlm.nih.gov/igblast/igblast.cgi?CMD=Web&SEARCH_TYPE=TCR&LINK_LOC=igtab) and translated by Expasy (web.expasy.org/translate/). The variable family is determined and fused to the CDR3 and junction (J or DJ) from the translated sequence. The variable sequence is fused to the murine constant sequence and the reconstructed TCRalpha and TCRbeta are linked by furin-flexible-P2A (RAKR-SGSG-ATNFSLLKQAGDVEENPGP) (SEQ ID NO: 26). Then the sequence is synthesized into DNA de novo and cloned into an expression vector (gamma-retrovirus or SLEEPING BEAUTY (SB) transposon (University of Minnesota, Minneapolis, MN)). T cells are then made to express the TCR using the standard viral transduction or non-viral transposition protocols and T cells expressing murinized TCRs (as detected by mouse TCR beta constant chain) are tested against the putative peptide.

[0154] Autologous APCs were transfected with TMG encoding irrelevant mutations, WT p53 sequences or mutated p53 sequences including p53-R248W. Media alone and PMA and

Ionomycin were negative and positive controls, respectively. TIL from patient 4273 (fragment cultures 8 and 15) were co-cultured overnight at 37 °C with TMG transfected APCs. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes → living cells (PI negative) → CD3+ (T cells). The results are shown in Figure 33.

[0155] Autologous APCs were pulsed with 25 amino acid peptides corresponding to the WT or mutated p53-R248W neoepitope for 2 hours at 37 °C. TIL from patient 4273 (fragment culture 15) with specificity to p53-R248W were co-cultured overnight at 37 °C with peptide-pulsed APCs. DMSO was peptide vehicle. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes → living cells (PI negative) → CD3+ (T cells). The results are shown in Figure 34.

[0156] Autologous APCs were pulsed with 15 amino acid peptides from the p53-R248W neoepitope overlapping 14 amino acids. TIL from patient 4273 (fragment culture 15) with specificity to p53-R248W were co-cultured overnight at 37 °C with peptide-pulsed APCs. DMSO was peptide vehicle, media alone (T cells only) and PMA and ionomycin were controls. The 25 amino acid peptides (wt p53-R248 and mutated p53-R248W) were additional controls for the 15 amino acid peptides. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes → living cells (PI negative) → CD3+ (T cells) → CD4+CD8-. The results are shown in Figure 35.

[0157] Cos7 cells (2.5×10^4 per well) were plated on wells of flat-bottom 96 well plates. The following day, cells were co-transfected with individual HLA alleles from patient 4273 and either WT or mutated TP53 TMG with or without the p53-R248W neoantigen, respectively. The following day, TIL with specificity to p53-R248W from Patient 4273 (fragment culture 15) were co-cultured with transfected Cos7 cells overnight at 37 °C. Secretion of IFN- γ was evaluated by ELISA. The results are shown in Figure 36.

[0158] T cells expressing mock (no TCR) or 4273-TCR1a2 were co-cultured with autologous APCs which were pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R248 sequence or mutated p53-R248W sequence. Media alone and PMA and Ionomycin were negative and positive controls, respectively. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated by ELISPOT. The results are shown in Figure 37.

[0159] The sequence of TCR 4273-TP53-R248W-TCR1a1, which was isolated from Patient 4273, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 437), the second underlined region is the CDR2alpha (SEQ

ID NO: 438), the third underlined region is the CDR3alpha (SEQ ID NO: 439), the fourth underlined region is the CDR1beta (SEQ ID NO: 440), the fifth underlined region is the CDR2beta (SEQ ID NO: 441), and the sixth underlined region is the CDR3beta (SEQ ID NO: 442). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 443) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 444) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 445) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 446) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

TCR name: 4273-TP53-R248W-TCR1a1

Recognition of p53 mutation: R248W

Method: p53 “hotspot” mutation universal screening

MASLRVLLVILWLQLSWVWSQQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFW
 YRQYSGKSPELIMFIYSNGDKEDGRFTAQLNKASQYVSLIRDSQPSDSATYLCAVTL
CGGYNKLIFGAGTRLAVHPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMES
GTFITDKCVLDMKAMDSKSNGAIAWSNQTSTFCQDIFKETNATYPSSDVPCDATLTEKSFE
TDMNLNFQNLVIVLRILLKLVAGFNLLMTLRLWSSRAKRSGSGATNFSLLKQAGDVE
ENPGPMHNQVLCVVLCLGANTVDGGITQSPKYLFRKEGQNVTLSCQNLNHDA
 MYWYRQDPGQGLRLIYYSQIVNDFQKGDIVEGYSVSREKKESFPLTVTSAQKNPTAF
YLCASSRDYEQYFGPGTRTLVTEDLRNVTPPKVSLFEPKAEIANKQKATLVCLARGFF
PDHVELSWVWNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRQCQVQF
HGLSEEDKWPEGSPKPVTONISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVL
VSTLVVMAMVKRKNS (SEQ ID NO: 563)

[0160] The sequence of TCR 4273-TP53-R248W-TCR1a2, which was isolated from Patient 4273, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 447), the second underlined region is the CDR2alpha (SEQ ID NO: 448), the third underlined region is the CDR3alpha (SEQ ID NO: 449), the fourth underlined region is the CDR1beta (SEQ ID NO: 450), the fifth underlined region is the CDR2beta (SEQ ID NO: 451), and the sixth underlined region is the CDR3beta (SEQ ID NO: 452). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the

first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 453) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 454) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 455) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 456) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

TCR name: 4273-TP53-R248W-TCR1a2

Recognition of p53 mutation: R248W

Method: p53 “hotspot” mutation universal screening

MASLRVLLVILWLQLSWVWSQOKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFW
 YRQYSGKSPELIMFIYSNGDKEDGRFTAQLNKASQYVSLLRDSQPSDSATYLCAVTL
SGGYNKLIFGAGTRLAVHPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMES
GTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFE
TDMNLNFQNLVIVLRILLKLVAGFNLLMTLRLWSSRAKRSGSGATNFSLLKQAGDVE
ENPGPMHNQVLCVFLCFLGANTVDGGITQSPKYLFRKEGQNVTLSCEQNLNHDA
 MYWYRQDPGQGLRLIYYSQIVNDFQKGDIVEGYVSREKKESFPLTVTSAQKNPTAF
 YLCASSRDYEQYFGPGTRLTVTEDLRNVTTPPKVSLFEPKAEIANKQKATLVCLARGFF
 PDHVELSWVWNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQF
 HGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVL
 VSTLVVMAMVKRKNS (SEQ ID NO: 564)

[0161] The statistics for the TCRs of Patient 4273 are set forth in Table 8 below. In Table 8, 96 total wells sorted with 41BB+ T cells after co-culture with mutated p53 protein (TMG or peptide). 77 wells had productive pairs (meaning had (1) a sequence and (2) no stop codons in the sequence) for a pairing frequency of 80.2%. 43 of those pairs were the CDR3A/CDR3B combination to make 4273-TP53-R248W-TCR1a1 (55.8% of the productive pairs). 30 of those pairs were the CDR3A/CDR3B combination to make 4273-TP53-R248W-TCR1a2 (39% of the productive pairs). Overall, the CDR3A and CDR3B for 4273-TP53-R248W-TCR1a1 were found 50 and 83 times, respectively, out of 96 wells. Overall, the CDR3A and CDR3B for 4273-TP53-R248W-TCR1a2 were found 33 and 83 times, respectively, out of 96 wells.

TABLE 8

TCR name	4273-TP53-R248W-TCR1a1	4273-TP53-R248W-TCR1a2
CDR3a	CAVTLCGGYNKLIF (SEQ ID NO: 439)	CAVTLSGGYNKLIF (SEQ ID NO: 449)
CDR3b	CASSSRDYEQYF (SEQ ID NO: 442)	CASSSRDYEQYF (SEQ ID NO: 452)
total wells	96	
total CDR3a/CDR3b pairs	77	
% paired	80.21%	
# times CDR3a	50	33
# times CDR3b	83	83
paired CDR3a/CDR3b	43	30
% of paired CDR3a/CDR3b pairs	55.84%	38.96%

EXAMPLE 7

[0162] This example demonstrates the identification of anti-mutated p53 T cells in Patient 4149. This example also demonstrates the isolation of one anti-mutated p53 TCR from patient 4149.

[0163] Experiments were carried out as described for Figures 15-18 for Patient 4149. The TCR was found using the Tran method. The TCR was then used to validate the “p53 hotspot mutation universal screening” method.

[0164] A TCR (4149-TCRa2b1 or 4149-TCRa2b2) was transposed into autologous PBL from patient 4149 and co-cultured with autologous APCs which were (1) electroporated with TMG composed of irrelevant, WT p53, or mutated p53 sequence or (2) pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-Y220 sequence or mutated p53-Y220C sequence. Combination of PMA and ionomycin was positive control. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 15. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes \rightarrow living cells (PI negative) \rightarrow CD3⁺ (T cells) \rightarrow CD4⁺ mTCR⁺ (TCR transposed T cells). The results are shown in Figure 16.

[0165] The percentage of CD4⁺4-1BB⁺ cells by TCRAD deep sequencing and TCRB deep sequencing was also performed. The results are shown in Table 9.

TABLE 9

TCR name	CDR3 α (% of CD4+41BB+ by TCRAD deep sequencing)	CDR3 β (% of CD4+41BB+ by TCRB deep sequencing)
4149-TCR-a2b1	20%	66%
4149-TCR-a2b2	20%	18%

[0166] Mapping of putative p53^{Y220C} minimal epitope recognized by 4149-F11: Autologous DC cells were peptide pulsed (10 μ g/mL) and rested overnight in granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4. TIL were rested for 2-3 days in 500 CU/mL IL-2. 2×10^4 TIL and 10^5 target cells were co-cultured overnight at 37 °C. IFN- γ was measured by ELISPOT. The results are shown in Table 10. 4-1BB expression was measured by FACS with the gate lymphocytes\PI(neg)CD3+\CD3+CD4+. The results are shown in Figure 17.

TABLE 10

Peptide No.	ELISPOT Result Positive (+) or negative (-) for IFN- γ production	Peptide	SEQ ID NO:
0	-	Vehicle	Not applicable
1	+	DRNTFRHSVVVP <u>C</u> EP	508
2	+	RNTFRHSVVVP <u>C</u> EPP	509
3	+	NTFRHSVVVP <u>C</u> EPPE	510
4	+	TFRHSVVVP <u>C</u> EPPEV	511
5	+ (weak)	FRHSVVVP <u>C</u> EPPEVG	512
6	-	RHSVVVP <u>C</u> EPPEVGS	513
7	-	HSVVVP <u>C</u> EPPEVGSD	514
8	-	SVVVVP <u>C</u> EPPEVGSDC	515
9	-	VVVVP <u>C</u> EPPEVGSDCT	516

Peptide No.	ELISPOT Result Positive (+) or negative (-) for IFN- γ production	Peptide	SEQ ID NO:
10	-	VVP <u>C</u> EPPEVGS DCTT	517
11	-	VP <u>C</u> EPPEVGS DCTTI	518

[0167] Cos7 cells (2.5×10^4 per well) were plated on wells of flat-bottom 96 well plates. After 20 hours, cells were co-transfected with individual HLA alleles with or without TMGs. After 20 hours, autologous DC cells were transfected with TMG in parallel. All HLA Class-II alleles were co-transfected into one set of wells with or without TMG. Cells not transfected with TMG were pulsed with p53-Y220C 15-mer peptide for 2-3 hours at 37 °C at 10 μ g/mL. After washing, 4149-TCRa2b2-transposed T cells (10^5) at day+14 of second REP were added to wells and co-cultured overnight at 37 °C. IFN- γ secretion was measured by ELISA. The results are shown in Figure 18. Prediction (Table 11) by NetMHCIIpan: cbs.dtu.dk/services/NetMHCIIpan/.

TABLE 11

HLA	Peptide	Affinity, nM	Rank
DRB3*02:02	N T FRHSVVVP <u>C</u> EPPE (SEQ ID NO: 510)	433.8	17

[0168] DRB3*02 expression was detected in 1367 of 3719 (37%) of DRB_ typed patients in the NCI HLA database and in 5 of 9 (56%) endometrial and ovarian cancer patients at NCI-SB. The reported frequency of the DRB3*02 allele is very high.

[0169] The sequence of TCR **4149TCRa2b2**, which was isolated from Patient 4149, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 57), the second underlined region is the CDR2alpha (SEQ ID NO: 58), the third underlined region is the CDR3alpha (SEQ ID NO: 59), the fourth underlined region is the CDR1beta (SEQ ID NO: 60), the fifth underlined region is the CDR2beta (SEQ ID NO: 61), and the sixth underlined region is the CDR3beta (SEQ ID NO: 62). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized

region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 63) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 64) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 65) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 66) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0170] Cancer reactive T cells were identified using the screening method set forth below. The p53 reactive cells for this patient were identified by the method described in U.S. Application No. 2017/0224800 (“Tran method”).

TCR name: 4149TCRa2b2

Recognition of p53 mutation: Y220C

Screening method: Used to validate the p53 “hotspot” mutation universal screening (the latter is given)

Co-culture to identify TCR: Co-culture 4149-F11 TIL fragment with p53-Y220C long peptide, sorted CD4+41BB+ T cells

Method to identify TCR: Frequency pairing. CD4+41BB+ sorted T cells were expanded in REP and the resulting T cell culture was subjected to TCRAD (alpha) and TCRB (beta) deep sequencing by Adaptive Biotechnologies. I paired the top two TCR alphas with the top two TCR betas in a matrix of 4 total TCRs. The second TCR alpha and second TCR beta was the reactive TCR hence TCRa2b2 nomenclature.

Abundance of TCR amongst all TCRs: as below

TCR orientation: alpha-beta

Expression vector: SB transposon

MASAPISMLAMLFTLSGLRAQSVAQPEDQVNVVAEGNPLTVKCTYSVSGNPYLFWYV
 QYPNRGLQFLLKYITGDNLVKGSYGFEAEFNKSQTSFHLKKPSALVSDSALYFC~~AVR~~
~~VWDYKLSFGAGTTVTVRANIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESG~~
~~TFITDKCVLDMKAMDSKSNGAIAWSNQTSTFCQDIFKETNATYPSSDVPCD~~ATL~~TEKSFET~~
~~DMNLNFQNLVIVLRILLKLVAGFNLLMTLRLWSSRAKRS~~SG~~GATNFSLLKQAGDVEE~~
~~NPGPMHNQVLCCVFLCFLGANTVDGGITQSPKYLFRKEGQNVTL~~SCEQNL~~NHDAM~~
~~YWYRQDPGQGLRLIYYSQIVNDFQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFY~~
~~LCASSISAGGDGYTFGSGTRLTVVEDLRNVTPPKVSLFEPKAEIANKQKATLVCLARGF~~
~~FPDHVELSWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNP~~RNH~~FRCQVQ~~
~~FHGLSEEDKWPEGSPKPVTONISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAV~~
~~LVSTLVVMAMVKRKNS~~ (SEQ ID NO: 565)

[0171] The statistics for TCR **4149TCRa2b2** of Patient 4149 are set forth in Table 12 below.

TABLE 12

CDR3	Rank of unique, productive CDR3s	CDR3 Counts	CDR3 Frequency
Alpha: CAVRVWDYKLSF (SEQ ID NO: 59)	2 of 4,308	648,707 of 3,309,400	19.6 %
Beta: CASSISAGGDGYTF (SEQ ID NO: 62)	2 of 3,176	104,325 of 578,948	18.0 %

EXAMPLE 8

[0172] This example demonstrates the identification of anti-mutated p53 T cells in Patient 4213 by co-culturing autologous APCs induced to express mutated p53 within autologous T cells (“p53 hotspot mutation universal screening”). This example also demonstrates the isolation of twelve anti-mutated p53 TCRs from patient 4213.

[0173] Experiments were carried out as described for Figures 19-20 for Patient 4213.

[0174] TIL fragments (F2 and F24) from patient 4213 were co-cultured with autologous APCs pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25-amino acid peptides composed of the mutated p53-R248Q sequence. Co-cultures were performed overnight at 37 °C. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes → living cells (PI negative) → CD3+ (T cells). The results are shown in Figure 19. CD8+4-1BB+ T cells were sorted into wells of 96 wells plates. TCRs were identified using single-cell RT-PCR.

[0175] CD4+ T cells came from patient 4213’s peripheral blood lymphocytes. The CD4+ T cell culture was co-cultured with autologous APCs pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25-amino acid peptides composed of the mutated p53-R248Q sequence. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated by ELISPOT. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes → living cells (PI negative) → CD3+ (T cells). The results are shown in Figure 20. CD4+41BB+ T cells were sorted into wells of 96 wells plates. TCRs were identified using single-cell RT-PCR.

[0176] The sequence of **4213-F2-TCR1**, which was isolated from Patient 4213, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 317), the second underlined region is the CDR2alpha (SEQ ID NO: 318), the third underlined region is the CDR3alpha (SEQ ID NO: 319), the fourth underlined region is

the CDR1beta (SEQ ID NO: 320), the fifth underlined region is the CDR2beta (SEQ ID NO: 321), and the sixth underlined region is the CDR3beta (SEQ ID NO: 322). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 323) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 324) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 325) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 326) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0177] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4213-F2-TCR1

Recognition of p53 mutation: R248Q

Screening method: p53 "hotspot" mutation universal screening

Co-culture to identify TCR: Co-culture 4213-F2 with R248Q long peptide, sorted CD8+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 8.3% (observed 2 times of 24 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAMLLGASVLILWLQPDWVNSQQKNDDQQVKQNSPSLSVQEGRISILNCDYTNSMF
 DYFLWYKKYPAEGPTFLISSIKDKNEDGRFTVFLNKS AKHLSLHIVPSQPGDSAVYF
 CAANTGNQFYFGTGTSLTVIPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTME
 SGTFITDKCVLDMKAMD SKSNGAIAWSNQTSTFCQDIFKETNATYPSSDVPCD ATLTEKSF
 ETDMNLNFQNLLVIVLRILLKLVAGFNLLMTLRLWSSRAKRSGSGATNFSLKQAGDV
 EENPGPMHTRLLCWAALCLLGAELTEAGVAQSPRYKII EKRSVAFWCNPISGHATL
 YWYQQILGQGPKLLIQFNNGVVDDSQLPKDRFSAERLKGVDSTLKI QPAKLEDSAV
 YLCASSHLAGEFYNEQFFGPGTRLTVLEDLRNVTPPKVSLFEP SKAEIANKQKATLVCLA
 RGFFPDHVELSWVWNGKEVHSGVCTDPQAYKESNYSYCLSSRLRV SATFWHNP RNHFRC
 QVQFHGLSEEDKWPEGSPKPVTONISAEAWGRADCGITSASYQQGVLSATILYEILLGKAT
 LYAVLVSTLVVMAMV KRKNS (SEQ ID NO: 566)

[0178] The statistics for TCR **4213-F2-TCR1** of Patient 4213 are set forth in Table 13 below.

TABLE 13

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	3	3.1%
CDR3beta	8	8.3%
4213-F2-TCR1 pairs	2	2.1%
Total paired TCRs	24	25.0%

[0179] The sequence of **4213-F2-TCR2**, which was isolated from Patient 4213, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 327), the second underlined region is the CDR2alpha (SEQ ID NO: 328), the third underlined region is the CDR3alpha (SEQ ID NO: 329), the fourth underlined region is the CDR1beta (SEQ ID NO: 330), the fifth underlined region is the CDR2beta (SEQ ID NO: 331), and the sixth underlined region is the CDR3beta (SEQ ID NO: 332). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 333) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 334) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 335) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 336) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0180] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4213-F2-TCR2

Recognition of p53 mutation: R248Q

Screening method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: Co-culture 4213-F2 with R248Q long peptide, sorted CD8+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 12.5% (observed 3 times of 24 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAGAFLLYVSMKMGGTAGQSLEQPSEVTAVEGAIVQINCTYQTSGFYGLSWYQQH
DGGAPTFLSYNALDGLEETGRFSSFLSRSDSYGYLLLQELQMKDSASYFCAFAYGQN

FVFGPGTRLSVLPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKC
VLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETDMNLNF
QNLLVIVLRILLKLVAGFNLLMTLRLWSSRAKRSGSGATNFSLLKQAGDVEENPGPMH
 FRLCCVAFCLLGAGPVDSGVTQTPKHLITATGQRVTLRCSPRSGDLSVYWYQQSLD
 QGLQFLIQYYNGEERAKGNILERFSAQQFPDLHSELNLSSLELGDSALYFCASSPLGD
SGNTIYFGEGSWLTVVEDLRNVTPPKVSLFEPKAEIANKQKATLVCLARGFFPDHVELS
WWWNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEED
 KWPEGSPKPVTQNISAEAWGRADCGITSASYQOGVLSATILYEILLGKATLYAVLVSTLVVM
 AMVKRKNS (SEQ ID NO: 567)

[0181] The statistics for TCR **4213-F2-TCR2** of Patient 4213 are set forth in Table 14 below.

TABLE 14

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	4	4.2%
CDR3beta	4	4.2%
4213-F2-TCR2 pairs	3	3.1%
Total paired TCRs	24	25.0%

[0182] The sequence of **4213-F2-TCR3**, which was isolated from Patient 4213, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 337), the second underlined region is the CDR2alpha (SEQ ID NO: 338), the third underlined region is the CDR3alpha (SEQ ID NO: 339), the fourth underlined region is the CDR1beta (SEQ ID NO: 340), the fifth underlined region is the CDR2beta (SEQ ID NO: 341), and the sixth underlined region is the CDR3beta (SEQ ID NO: 342). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 343) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 344) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 345) includes the sequence starting from the amino terminus and ending immediately prior to the

start of the linker. The full-length beta chain (SEQ ID NO: 346) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0183] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4213-F2-TCR3

Recognition of p53 mutation: R248Q

Screening method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: Co-culture 4213-F2 with R248Q long peptide, sorted CD8+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 70.8% (observed 17 times of 24 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MATLLGVSLVILWLQLARVNSQQGEEDPQALSIQEGENATMNC SYKTSINN LQWYR
 QNSGRGLVHLILIRSNEREKHSGRRLRVTLDTSKKSSLLITASRAADTASYFCATDAW
NNDMRFGAGTRLTVPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTF
 ITDKCVLDMKAMDSKSNGAIAWSNQTSTFCQDIFKETNATYPSSDVPCDATLTEKSFETD
 MNLNFQNLVIVLRILLKLVAGFNLLMTLRLWSSRAKRS GSGATNFSLLKQAGDVEEN
PGPMHIGLLCCVAFSLLWASPVNAGVTQTPKFQVLKTGQSMTLQCAQDMNHNSMY
 WYRQDPGMGLRLIYYSASEGTTDKGEVPNGYNVSRNLN KREFSLRLESAAPSQTSVYF
CASSESGNTEAFFGQGTRLTVVEDLRNVTPPKVSLFEP SKAEIANKQKATLVCLARGFF
 PDHVELSWVWNGKEVHSGVCTDPQAYKESNYSYCLSSRLRV SATFWHNP RNHFRCQVQF
 HGLSEEDKWPEGSPKPVTONISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVL
 VSTLVVMAMVKRKNS (SEQ ID NO: 568)

[0184] The statistics for TCR **4213-F2-TCR3** of Patient 4213 are set forth in Table 15 below.

TABLE 15

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	19	19.8%
CDR3beta	42	43.8%
4213-F2-TCR3 pairs	17	17.7%
Total paired TCRs	24	25.0%

[0185] The sequence of **4213-F24-TCRa1**, which was isolated from Patient 4213, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha

(SEQ ID NO: 347), the second underlined region is the CDR2alpha (SEQ ID NO: 348), the third underlined region is the CDR3alpha (SEQ ID NO: 349), the fourth underlined region is the CDR1beta (SEQ ID NO: 350), the fifth underlined region is the CDR2beta (SEQ ID NO: 351), and the sixth underlined region is the CDR3beta (SEQ ID NO: 352). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 353) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 354) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 355) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 356) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0186] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4213-F24-TCRa1

Recognition of p53 mutation: R248Q

Screening method: p53 "hotspot" mutation universal screening

Co-culture to identify TCR: Co-culture 4213-F24 with R248Q long peptide, sorted CD8+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 15.9% (observed 7 times of 44 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAKHLTTFLVILWLYFYRGNNGKNQVEQSPQSLIILEGKNCTLQCNYTVSPFSNLRWY
 KQDTGRGPVSLTIMTFSENTKSNGRYTATLDADTKQSSLHITASQLSDSSASYICVVSS
YKIIFGTGTRLHVFPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITD
 KCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETDMNL
NFQNLLVIVLRILLKVAGFNLLMTLRLWSSRAKRSGSGATNFSLLKQAGDVEENPGP
 MHTRLLFWVAFCLLGAYHTGAGVVSQSPSNKVTEKGDVELRCDPISGHTALYWYR
 QRLGQGLEFLIYFQGNSAPDKSGLPSDRFSAERTGESVSTLTIQRTQQEDSAVYLCAS
SPIQGENSPLHFGNGTRLTVEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPD
 HVELSWWWNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHG
 LSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVST
 LVVMAMVKKNS (SEQ ID NO: 569)

[0187] The statistics for TCR **4213-F24-TCRa1** of Patient 4213 are set forth in Table 16 below.

TABLE 16

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	7	7.3%
CDR3beta	80	83.3%
4213-F24-TCRa1 pairs	7	7.3%
Total paired TCRs	44	45.8%

[0188] The sequence of **4213-F24-TCRa2**, which was isolated from Patient 4213, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 357), the second underlined region is the CDR2alpha (SEQ ID NO: 358), the third underlined region is the CDR3alpha (SEQ ID NO: 359), the fourth underlined region is the CDR1beta (SEQ ID NO: 360), the fifth underlined region is the CDR2beta (SEQ ID NO: 361), and the sixth underlined region is the CDR3beta (SEQ ID NO: 362). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 363) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 364) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 365) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 366) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0189] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4213-F24-TCRa2

Recognition of p53 mutation: R248Q

Screening method: p53 "hotspot" mutation universal screening

Co-culture to identify TCR: Co-culture 4213-F24 with R248Q long peptide, sorted CD8+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 84.1% (observed 37 times of 44 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAKHLTTFVLVILWLYFYRGNNGKNQVEQSPQSLIILEGKNCTLQCNYTVSPFSNLRWY
 KQDTGRGPVSLTIMTFSENTKSNGRYTATLDADTKQSSLHITASQLSDSASYICVVSS
YKLIFGTGTRLQVFPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITD
 KCVLDMKAMD~~SKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETDMNL~~
 NFQ~~NLLVIVLRILLKLVAGFNLLMTRLRLWSSRAKRSGSGATNFSLLKQAGDVEENPGP~~
 MHTRLFWVAFCLLGAYHTGAGVVSQSPSNKVTEKGKDVELRCDPISGHTALYWYR
 QRLGQGLEFLIYFQGNSAPDKSGLPSDRFSAERTGESVSTLTIQRTQQEDSAVYLCAS
SPIQGENSPLHFGNGTRRLTVTEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPD
 HVELSWWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHG
 LSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGATLYAVLVST
 LVVMAMVKKRNS (SEQ ID NO: 570)

[0190] The statistics for TCR **4213-F24-TCRa2** of Patient 4213 are set forth in Table 17 below.

TABLE 17

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	39	40.6%
CDR3beta	80	83.3%
4213-F24-TCRa2 pairs	37	38.5%
Total paired TCRs	44	45.8%

[0191] The sequence of **4213-PBL-TCR1**, which was isolated from Patient 4213, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 367), the second underlined region is the CDR2alpha (SEQ ID NO: 368), the third underlined region is the CDR3alpha (SEQ ID NO: 369), the fourth underlined region is the CDR1beta (SEQ ID NO: 370), the fifth underlined region is the CDR2beta (SEQ ID NO: 371), and the sixth underlined region is the CDR3beta (SEQ ID NO: 372). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 373) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 374) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 375)

includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 376) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0192] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4213-PBL-TCR1

Recognition of p53 mutation: R248Q

Screening method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: CD4+ Memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide and CD4+41BB+ T cells were sorted

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 9.5% (observed 6 times of 63 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MALLLVPAFQVIFTLGGTRAQSVTQLDSQVPVFEEAPVELRCNYSSSVSVYLFWYVQ
 YPNQGLQLLLKYLSGSTLVESINGFEAEFNKSQTSFHLRKPSVHISDTAEYFCAVSKG
 TGAQKLVFGQGTRLTINPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGT
 FITDKCVLDMKAMD~~SKS~~NGALAWSNQT~~SFT~~CQDIFKETNATYPSSDVP~~CD~~ATL~~TE~~KSFETD
 MNLNFQ~~NLL~~VIVLR~~LLLL~~KVAGFNLL~~MTLRL~~WSSRAK~~R~~SGSGATN~~F~~SLLKQAGDVEEN
 PGP~~MHN~~QVLC~~CV~~LCFLGANTVDGGITQSPKYLFRKEGQNV~~TL~~SCEQN~~L~~NHDAMY
 WYRQDPGQGLRLIYYSQIVNDFQKGDIAEGYSVSREKKESFPLIVTSAQKNPTASYLC
 ASEAFFGQGTRLTVVEDLRNVTPPKVSLFEP~~SKAE~~IANKQKATLVCLARGFFPDHVELSW
 WVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFR~~CQ~~VQFHGLSEEDK
 WPEGSPKPV~~TQ~~NISAEAWGRADCGITSASYQ~~Q~~GVLSATILYEILLGKATLYAVLVSTLVVMA
 MVKRKNS (SEQ ID NO: 571)

[0193] The statistics for TCR 4213-PBL-TCR1 of Patient 4213 are set forth in Table 18 below.

TABLE 18

Parameter	#	Frequency
Total wells	192	100%
CDR3alpha	9	4.7%
CDR3beta	6	3.1%
4213-PBL-TCR1 pairs	6	3.1%
Total paired TCRs	63	32.8%

[0194] The sequence of **4213-PBL-TCR2**, which was isolated from Patient 4213, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 377), the second underlined region is the CDR2alpha (SEQ ID NO: 378), the third underlined region is the CDR3alpha (SEQ ID NO: 379), the fourth underlined region is the CDR1beta (SEQ ID NO: 380), the fifth underlined region is the CDR2beta (SEQ ID NO: 381), and the sixth underlined region is the CDR3beta (SEQ ID NO: 382). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 383) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 384) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 385) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 386) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0195] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4213-PBL-TCR2

Recognition of p53 mutation: R248Q

Screening method: p53 "hotspot" mutation universal screening

Co-culture to identify TCR: CD4+ Memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide and CD4+41BB+ T cells were sorted

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 7.9% (observed 5 times of 63 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MALVTSITVLLSLGIMGDAKTTQPNSMESNEEEPVHLPCNHSTISGTDYIHWYRQLPS
 QGPEYVIHGLTSNVNNRMASLAI AEDRKSSTLILHRATLRDAAVYYCILASGAGSYQ
LTFGKGTKLSVIPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKC
 VLDMKAMD SKSNGAIAWSNQT SFTCQDIFKETNATYPSSDVPCDATL TEKSFETDMNLNF
 QNLLVIVLRILLKLVAGFNLLMTLRLWSSRAKRSGSGATNFSLLKQAGDVEENPGPMH
 CRLCCVVFCLLQAGPLDTAVSQTPKYLVTQMGNDSIKCEQNLGHDTMYWYKQD
 SKKFLKIMFSYNNKELIINETVPNRFPKSPDKAHLNLHINSLELGDSAVYFCASRTIG
YNTEAFFGQGTRLTVVEDLRNVTPPKVSLFEP SKAEIANKQKATLVCLARGFFPDHVELS
 WWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNP RNHFRCQVQFHGLSEED
 KWPEGSPKPVTONISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVVM
 AMVKRKNS (SEQ ID NO: 572)

[0196] The statistics for TCR **4213-PBL-TCR2** of Patient 4213 are set forth in Table 19 below.

TABLE 19

Parameter	#	Frequency
Total wells	192	100%
CDR3alpha	8	4.2%
CDR3beta	8	4.2%
4213-PBL-TCR2 pairs	5	2.6%
Total paired TCRs	63	32.8%

[0197] The sequence of **4213-PBL-TCR3**, which was isolated from Patient 4213, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 387), the second underlined region is the CDR2alpha (SEQ ID NO: 388), the third underlined region is the CDR3alpha (SEQ ID NO: 389), the fourth underlined region is the CDR1beta (SEQ ID NO: 390), the fifth underlined region is the CDR2beta (SEQ ID NO: 391), and the sixth underlined region is the CDR3beta (SEQ ID NO: 392). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 393) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 394) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 395) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 396) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0198] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4213-PBL-TCR3

Recognition of p53 mutation: R248Q

Screening method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: CD4+ Memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide and CD4+41BB+ T cells were sorted

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 6.3% (observed 4 times of 63 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAKIRQFLAILWLQLSCVSAAKNEVEQSPQNLTAQEGEFITINCSYSVGISALHWLQ
 QHPGGGIVSLFMLSSGKKKHGRLIATINIQEKHSSLHITASHPRDSA VYICAALS YNTD
KLIFGTGTRLQVFPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDK
 CVLDMKAMDSKSNGAIAWSNQTSTFCQDIFKETNATYPSSDVPCDATLTEKSFETDMNLN
 FQNLLVIVI.RILLKLVAGFNLLMTLRLWSSRAKRSGSGATNFSLKQAGDVEENPGPM
 HTRLLCWAALCLLGADHTGAGVSQTPSNKVTEKGKYVELRCDPISGHTALYWYRQS
 LGQGPEFLIYFQGTGAADDSGLPNDRFFAVRPEGSVSTLKIQRTERGDSAVYLCASSL
SGLLQETQYFGPGTRLLVLEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDHV
 ELSWWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNP RNHFRCQVQFHGLS
 EEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTL
 VVMAMVKRKNS (SEQ ID NO: 573)

[0199] The statistics for TCR **4213-PBL-TCR3** of Patient 4213 are set forth in Table 20 below.

TABLE 20

Parameter	#	Frequency
Total wells	192	100%
CDR3alpha	4	2.1%
CDR3beta	7	3.6%
4213-PBL-TCR3 pairs	4	2.1%
Total paired TCRs	63	32.8%

[0200] The sequence of **4213-PBL-TCR4a1**, which was isolated from Patient 4213, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 397), the second underlined region is the CDR2alpha (SEQ ID NO: 398), the third underlined region is the CDR3alpha (SEQ ID NO: 399), the fourth underlined region is the CDR1beta (SEQ ID NO: 400), the fifth underlined region is the CDR2beta (SEQ ID NO: 401), and the sixth underlined region is the CDR3beta (SEQ ID NO: 402). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second

italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 403) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 404) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 405) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 406) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0201] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4213-PBL-TCR4a1

Recognition of p53 mutation: R248Q

Screening method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: CD4+ Memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide and CD4+41BB+ T cells were sorted

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 3.2% (observed 2 times of 63 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAYSPGLVSLILLLLGRTRGNSVTQMEGPVTLSEEAFLTINCTYATGYP~~SLFWYVQ~~
 YPGEGLQLLLKATKADDKGSNKGFEATYRKETTSFHLEKGSVQVSDSAVYFCALSH
 TGSSNTGKLIFGQGTRLQVKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTME
 SGTFITDKCVLDMKAMD~~SKSNGAIAWSNQTSTFCQDIFKETNATYPSSDVPCD~~ATLLEKSF
 ETDMNLNFQ~~NLLVIVLRILL~~LKVAGFNLLMTLRLWSSRAKRS~~GSGATNFSLLKQAGDV~~
EENPGPMHTRLLCWAALCLLGAELTEAGVAQSPRYKIIEKRQSVAFWCNPISGHATL
 YWYQQILGQGPKLLIQFQ~~NNGVVDDSQLPKDRFSAERLKGVDSTLKIQPAKLED~~SAV
 YLCASSTGGGRHQ~~PQHFGDGTRLSILEDLRNVTPPKVSLFEP~~SKAEIANKQKATLVCLAR
 GFFPDHVELSW~~WVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRV~~SATFWHNP~~RNHFR~~CQ
 VQFHGLSEEDKW~~PEGSPKPVTONISAEAWGRADCGITSASYQQGVLSATILYEILLG~~KATLY
 AVLVSTLVVMAMV~~KRKNS~~ (SEQ ID NO: 574)

[0202] The statistics for TCR **4213-PBL-TCR4a1** of Patient 4213 are set forth in Table 21 below.

TABLE 21

Parameter	#	Frequency
Total wells	192	100%

Parameter	#	Frequency
CDR3alpha	2	1.0%
CDR3beta	36	18.8%
4213-PBL-TCR4a1 pairs	2	1.0%
Total paired TCRs	63	32.8%

[0203] The sequence of **4213-PBL-TCR4a2**, which was isolated from Patient 4213, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1 alpha (SEQ ID NO: 407), the second underlined region is the CDR2alpha (SEQ ID NO: 408), the third underlined region is the CDR3alpha (SEQ ID NO: 409), the fourth underlined region is the CDR1beta (SEQ ID NO: 410), the fifth underlined region is the CDR2beta (SEQ ID NO: 411), and the sixth underlined region is the CDR3beta (SEQ ID NO: 412). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 413) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 414) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 415) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 416) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0204] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4213-PBL-TCR4a2

Recognition of p53 mutation: R248Q

Screening method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: CD4+ Memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide and CD4+41BB+ T cells were sorted

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 3.2% (observed 2 times of 63 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAYSPGLVSLILLLLGRTRGNSVTQMEGPVTLSEEAFLTINCTYTATGYPSLFWYVQ
 YPG EGLQLLLKATKADDKGSNKGF EATYRKETTSFHLEKGSVQVSDSAVYFCALSQ
TGSSKTGKLIFGQGTRLQVKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTME
 SGTFITDKCVLDMKAMD SKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCD ATLTEKSF
 ETDMNLNFQNLVIVLRILLKLVAGFNLLMTLRLWSS**RAKRSGSGATNFSLLKQAGDV**
EENPGPMHTRLLCWAALCLLGAELTEAGVAQSPRYKII EKRSVAFWCNPISGHATL
 YWYQQILGQGPKLLIQFQNNGVVDDSQLPKDRFSAERLKGVDSTLKIQPAKLEDSAV
 YLCASSTGGGRHQPHFGDGTRLSILEDLRNVTPPKVSLFEP SKAEIANKQKATLVCLAR
 GFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNP RNHFRCQ
 VQFHGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLY
 AVLVSTLVVMAMVKKRNS (SEQ ID NO: 575)

[0205] The statistics for TCR **4213-PBL-TCR4a2** of Patient 4213 are set forth in Table 22 below.

TABLE 22

Parameter	#	Frequency
Total wells	192	100%
CDR3alpha	2	1.0%
CDR3beta	36	18.8%
4213-PBL-TCR4a2 pairs	2	1.0%
Total paired TCRs	63	32.8%

[0206] The sequence of **4213-PBL-TCR4a3**, which was isolated from Patient 4213, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 417), the second underlined region is the CDR2alpha (SEQ ID NO: 418), the third underlined region is the CDR3alpha (SEQ ID NO: 419), the fourth underlined region is the CDR1beta (SEQ ID NO: 420), the fifth underlined region is the CDR2beta (SEQ ID NO: 421), and the sixth underlined region is the CDR3beta (SEQ ID NO: 422). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 423) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 424) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 425) includes the sequence starting from the amino terminus and ending

immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 426) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0207] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4213-PBL-TCR4a3

Recognition of p53 mutation: R248Q

Screening method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: CD4+ Memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide and CD4+41BB+ T cells were sorted

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 4.8% (observed 3 times of 63 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAYSPGLVSLILLLLGRTRGNSVTQMEGPVTLSEEAFLTINCTYATATGYPSLFWYVQ
 YPGEGLQLLLKATKADDKGSNKGFEATYRKETTTFHLEKGSVQVSDSAVYFCALSQ
TGSSNTGKLIFGQGTRLQVKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTME
SGTFITDKCVLDMKAMDSSKNGALAWSNQTSTFCQDIFKETNATYPSSDVPCDATLTEKSF
ETDMNLNFQNLLVIVLRILLLLKVAGFNLLMTRLRLWSSRAKRSGSGATNFSLKQAGDV
EENPGPMHTRLLCWAALCLLGAELTEAGVAQSPRYKIIKRQSVAFWCNPISGHATL
YWYQQILGQGPKLLIQFQNNGVVDDSQLPKDRFSAERLKGVDSTLKIQPAKLEDSAV
YLCASSTGGGRHQPHFGDGTRLSILEDLRNVTTPPKVSLFEPSKAEIANKQKATLVCLAR
GFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRQ
VQFHGLSEEDKWPEGSPKPVTONISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLY
AVLVSTLVVMAMVKKRNS (SEQ ID NO: 576)

[0208] The statistics for TCR **4213-PBL-TCR4a3** of Patient 4213 are set forth in Table 23 below.

TABLE 23

Parameter	#	Frequency
Total wells	192	100%
CDR3alpha	4	2.1%
CDR3beta	36	18.8%
4213-PBL-TCR4a3 pairs	3	1.6%
Total paired TCRs	63	32.8%

[0209] The sequence of **4213-PBL-TCR4a4**, which was isolated from Patient 4213, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 427), the second underlined region is the CDR2alpha (SEQ ID NO: 428), the third underlined region is the CDR3alpha (SEQ ID NO: 429), the fourth underlined region is the CDR1beta (SEQ ID NO: 430), the fifth underlined region is the CDR2beta (SEQ ID NO: 431), and the sixth underlined region is the CDR3beta (SEQ ID NO: 432). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 433) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 434) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 435) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 436) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0210] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4213-PBL-TCR4a4

Recognition of p53 mutation: R248Q

Screening method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: CD4+ Memory T cells after in vitro sensitization with R248Q long peptide were co-cultured with R248Q long peptide and CD4+41BB+ T cells were sorted

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 3.2% (observed 2 times of 63 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAYSPGLVSLILLLLGRTRGNSVQTMEGPVTLSEEAF~~LT~~INCTYTATGYPSLFWYVQ
 YPGEGLQLLLKATKAD~~DK~~GSNKGFEATYRKETTSFHLEKGSVQVSDSAVYFCALSTT
 GSSNTGKLI~~F~~GGQTTLQVKPNI~~Q~~NPEPAVYQLKDPRS~~Q~~DSTLCLFTDFDS~~Q~~INVPKTMES
 GTFITDKCVLDMKAMDSKSN~~G~~AIAWSN~~Q~~TSFT~~C~~QDIFKETNATYPSSD~~V~~PCDATL~~T~~EKSFE
 TDMN~~N~~FN~~Q~~NLLVIVLRILLK~~V~~AGFNLLM~~T~~LRL~~W~~SS~~R~~AKRSGSGATNFSLLK~~Q~~AGDVE
 ENPGPMHTRLLCWAALCLLGAELTEAGVAQSPRYKII~~E~~KRQSVAFWCN~~P~~ISGHATLY
 WYQQILGQGP~~L~~LIQ~~F~~Q~~N~~NGV~~V~~DDSQLPKDRFSAERLKGVDSTLKIQPAKLEDSAVY
 LCASSTGGGRHQP~~H~~FGD~~G~~TRLSILE~~D~~LRN~~V~~TPPK~~V~~SLFEP~~S~~KAEIANK~~Q~~KATLVCLARG
 FFPDHVELS~~W~~W~~V~~NGKEVHSGVCTDPQAYKESNYSYCLSSRLRV~~S~~ATFWHNP~~R~~NHFRCQV

*QFHGLSEEDKWPEGSPKPVTQONISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYA
VLVSTLVVMAMVKRKNS* (SEQ ID NO: 577)

[0211] The statistics for TCR **4213-PBL-TCR4a4** of Patient 4213 are set forth in Table 24 below.

TABLE 24

Parameter	#	Frequency
Total wells	192	100%
CDR3alpha	2	1.0%
CDR3beta	36	18.8%
4213-PBL-TCR4a3 pairs	2	1.0%
Total paired TCRs	63	32.8%

EXAMPLE 9

[0212] This example demonstrates the identification of anti-mutated p53 T cells in Patient 4268 by co-culturing autologous APCs induced to express mutated p53 within autologous T cells (“p53 hotspot mutation universal screening”). This example also demonstrates the isolation of five anti-mutated p53 TCRs from patient 4268.

[0213] Experiments were carried out as described for Figures 21-24 for Patient 4268.

[0214] TIL fragments (F1-F24, n=24) from patient 4268 were co-cultured with autologous APCs electroporated with TMG composed of irrelevant, WT p53, or mutated p53 sequence. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 21.

[0215] TIL fragments (F1-F24, n=24) from patient 4268 were co-cultured with autologous APCs pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-R248 sequence or mutated p53-R248Q sequence. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 22.

[0216] TIL fragments (F1-F24, n=24) from patient 4268 were co-cultured with autologous APCs pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25-amino acid peptides composed of wt p53-R248 sequence or mutated p53-R248Q sequence. Co-cultures were performed overnight at 37 °C. Expression of 4-1BB was evaluated by flow

cytometry after gating for lymphocytes → living cells (PI negative) → CD3+ (T cells). The results are shown in Figures 23-24. TIL fragments F18 and F19 were sources of TCRs after sorting CD4+41BB+ T cells. TIL fragments F7, F8, and F15 were sources of TCRs after sorting CD8+4-1BB+ T cells.

[0217] The sequence of **4268-TCR1**, which was isolated from Patient 4268, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 137), the second underlined region is the CDR2alpha (SEQ ID NO: 138), the third underlined region is the CDR3alpha (SEQ ID NO: 139), the fourth underlined region is the CDR1beta (SEQ ID NO: 140), the fifth underlined region is the CDR2beta (SEQ ID NO: 141), and the sixth underlined region is the CDR3beta (SEQ ID NO: 142). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 143) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 144) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 145) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 146) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0218] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4268-TCR1

Recognition of p53 mutation: R248Q

Method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: Co-culture 4268-F7 and 4268-F8 with p53-R248Q long peptide, sorted CD8+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 78.7% (observed 48 times of 61 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MASLRVLLVILWLQLSWVWSQQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFW
 YRQYSGKSP~~ELIMFI~~YNSNGDKEDGRFTAQLNKASQYVSLIRDSQPSDSATYLCAVS
WYSTLTFGKGTMLLVSPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGT
FITDKCVLDMKAMDSKSNGAI~~AWSNQTSFTCQDIFKETNATYPSSD~~VPCDATLLEKSFETD
 MNLNFQ~~NLLVIVLRILL~~LLKVAGFNLLMTLRLWSSRAKRSGSGATNFSLLKQAGDVEEN
 PGP~~MHTRLFFYVALCLLWAGHRDAGITQSPRYKITETGRQV~~TLMCHQTWSHSYMF

WYRQDLGHGLRLIYYSAADITDKGEVPDGYVVSRSKTENFPLTLESATRSQTSVYF
CASSGSRTDTQYFGPGTRRLTVLEDLRNVTPPKVSLFEPKAEIANKQKATLVCLARGFFP
 DHVELSWVWNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNP RNHFRCQVQFH
 GLSEEDKWPEGSPKPVTONISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLV
 STLVVMAMVKRKNS (SEQ ID NO: 578)

[0219] The statistics for TCR **4268-TCR1** of Patient 4268 are set forth in Table 25 below.

TABLE 25

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	54	56.3%
CDR3beta	71	74.0%
4268-TCR1 pairs	48	50.0%
Total paired TCRs	61	63.5%

[0220] The sequence of **4268-TCR2**, which was isolated from Patient 4268, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 147), the second underlined region is the CDR2alpha (SEQ ID NO: 148), the third underlined region is the CDR3alpha (SEQ ID NO: 149), the fourth underlined region is the CDR1beta (SEQ ID NO: 150), the fifth underlined region is the CDR2beta (SEQ ID NO: 151), and the sixth underlined region is the CDR3beta (SEQ ID NO: 152). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 153) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 154) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 155) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 156) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0221] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4268-TCR2

Recognition of p53 mutation: R248Q

Method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: Co-culture 4268-F7 and 4268-F8 with p53-R248Q long peptide, sorted CD8+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 6.6% (observed 4 times of 61 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MALKFSVSILWIQLAWVSTQLLEQSPQFLSIQEGENLTVYCNSSSVFSSSLQWYRQEPG
 EGPVLLVTVVVTGGEVKKLKRLTFQFGDARKDSSLHITAAQP GDTGLYL CAGEFAGN
QFYFGTGTSLTVIPNIQNPEPAVYQLKDP RSQDSTLCLFTDFDSQINVPKTMESGTFITDK
 CVLDMKAMDSKSN GAIAWSNQT SFTCQDIFKETNATYPSSDVPCD ATLTEKSFETDMNLN
 FQ NLLVIVLRILL LKVAGFNLLMTLRLWSSRAKRSGGATNFSLLKQAGDVEENPGPM
 HCRLCCAVLCLLGA VPIDTEVTQTPKHLV MGMTNKKSLKCEQHMGHRAMYWYK
 QKAKKPELMFVYSY EKLSINESVPSRFSPEC PNSSLNLHLHALQPEDSALYLCASS
QVGLTYEQYFGPGTR LTVTEDLRNVTPPKVSLFEP SKAEIANKQKATLVCLARGFFPDH
 VELS WVVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRV SATFWHNP RNHFRCQVQFHGL
 SEEDKWPEGSPK PVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTL
 VVMAMVKRKNS (SEQ ID NO: 579)

[0222] The statistics for TCR **4268-TCR2** of Patient 4268 are set forth in Table 26 below.

TABLE 26

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	6	6.3%
CDR3beta	4	4.2%
4268-TCR2 pairs	4	4.2%
Total paired TCRs	61	63.5%

[0223] The sequence of **4268-TCR3**, which was isolated from Patient 4268, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 157), the second underlined region is the CDR2alpha (SEQ ID NO: 158), the third underlined region is the CDR3alpha (SEQ ID NO: 159), the fourth underlined region is the CDR1beta (SEQ ID NO: 160), the fifth underlined region is the CDR2beta (SEQ ID NO: 161), and the sixth underlined region is the CDR3beta (SEQ ID NO: 162). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is

the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 163) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 164) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 165) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 166) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0224] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4268-TCR3

Recognition of p53 mutation: R248Q

Method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: Co-culture 4268-F15 with p53-R248Q long peptide, sorted CD8+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 88.6% (observed 31 times of 35 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MASAPISMLAMLFTLSGLRAQSV AQPEDQVNVAEGNPLTVKCTYSVSGNPYLFWYV
 QYPNRGLQFLLKYITGDNLVKGSYGFEAEFNKSQTSFHLKKPSALVSDSALYFC AVR
 DNSGGSNYKLTFGKGTLLTVNPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKT
 MESGTFITDKCVLDMKAMD SKSNGAIAWSNQTSTFCQDIFKETNATYPSSDVPCDATLTE
 KSFETDMNLNFQNLVIVLRILLKLVAGFNLLMTRLRLWSSRAKRSGSGATNFSLLKQAG
DVEENPGPMHTRLLCWAALCLLGAELTEAGVAQSPRYKIIKRQSVAFWCNPISGH
ATLYWYQQILGQGPKLLIQFQNNGVVDDSQLPKDRFSAERLKGVDSTLKIQPAKLED
 SAVYLCASSLGQGQTQYFGPGTRLLVLEDLRNVTPPKVSLFEP SKAEIANKQKATLVCL
 ARGFFPDHVELSWVWNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFR
 CQVQFHGLSEEDKWPEGSPKPVTONISAEAWGRADCGITSASYQQGVLSATILYEILLGKA
 TLYAVLVSTLVVMAMVKRKNS (SEQ ID NO: 580)

[0225] The statistics for TCR **4268-TCR3** of Patient 4268 are set forth in Table 27 below.

TABLE 27

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	42	43.8%

Parameter	#	Frequency
CDR3beta	37	38.5%
4268-TCR3 pairs	31	32.3%
Total paired TCRs	35	36.5%

[0226] The sequence of **4268-TCR4**, which was isolated from Patient 4268, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 167), the second underlined region is the CDR2alpha (SEQ ID NO: 168), the third underlined region is the CDR3alpha (SEQ ID NO: 169), the fourth underlined region is the CDR1beta (SEQ ID NO: 170), the fifth underlined region is the CDR2beta (SEQ ID NO: 171), and the sixth underlined region is the CDR3beta (SEQ ID NO: 172). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 173) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 174) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 175) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 176) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0227] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4268-TCR4

Recognition of p53 mutation: R248Q

Method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: Co-culture 4268-F18 with p53-R248Q long peptide, sorted CD4+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 95.2% (observed 40 times of 42 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MALLLVPAFQVIFTLGGTRAQSVTQLDSQVPVFEEAPVELRCNYSSSVSVYLFWYVQ
 YPNQGLQLLLKYLSGSTLVESINGFEAEFNKSQTSFHLRKPSVHISDTAEYFCAVRGSS
 GTYKYIFGTGTRLKVLANIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTF
 ITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETD

*MNLNFQ*NLLVIVLRILLLLKVAGFNLLMTLRLWSS**RAKR**SGSGATNFSLLKQAGDVEEN
PGPMHIRLLCRVAFCFLAVGLVDVKVTQSSRYLVKRTGEKVFLECVQDMDHENMF
WYRQDPGLGLRLIYFSYDVKMKKEKGDIPEGYSVSREKKERFSLILESASTNQTSMYL
CASKGDQNTEAFFGQGTRLTVVEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFF
PDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCVQVQF
HGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSSATILYEILLGKATLYAVL
VSTLVVMAMVKRKNS (SEQ ID NO: 581)

[0228] The statistics for TCR **4268-TCR4** of Patient 4268 are set forth in Table 28 below.

TABLE 28

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	43	44.8%
CDR3beta	53	55.2%
4268-TCR4 pairs	40	41.7%
Total paired TCRs	42	43.8%

[0229] The sequence of **4268-TCR5**, which was isolated from Patient 4268, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 177), the second underlined region is the CDR2alpha (SEQ ID NO: 178), the third underlined region is the CDR3alpha (SEQ ID NO: 179), the fourth underlined region is the CDR1beta (SEQ ID NO: 180), the fifth underlined region is the CDR2beta (SEQ ID NO: 181), and the sixth underlined region is the CDR3beta (SEQ ID NO: 182). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 183) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 184) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 185) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 186) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0230] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4268-TCR5

Recognition of p53 mutation: R248Q

Method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: Co-culture 4268-F19 with p53-mut-TMG, sorted CD4+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 11.8% (observed 2 times of 17 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAGVFLLYVSMKMGTTGQNIDQPTMTATEGAIVQINCTYQTSGFNGLFWYQQH
 AGEAPTFLSYNVLDGLEEKGRFSSFLSRSGYSYLLKELQMKDSASYLCAVRDLQT
 GANNLFFGTGTRLTVIPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFI
 TDKCVLDMKAMDSKSNGAIAWSNQTSTFCQDIFKETNATYPSSDVPCDATLTEKSFETDM
 NLNFQNLVIVLRILLKLVAGFNLLMTLRLWSSRAKRSGSGATNFSLLKQAGDVEENP
 GPMHIRLLCRVAFCFLAVGLVDVKVTQSSRYLVKRTGKVFLECVQDMDHENMFW
 YRQDPGLGLRLIYFSYDVKMKEKGDPIEGYSVSREKKERFSLILESASTNQTSMYLCA
 SSLTFGTTEAFFGQGTRLTVVEDLRNVTPPKVSLFEPKAEIANKQKATLVCLARGFFPD
 HVELSWVWNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPVNHFRFCQVQFHG
 LSEEDKWPEGSPKPVTONISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVST
 LVVMAMVKKRNS (SEQ ID NO: 582)

[0231] The statistics for TCR **4268-TCR5** of Patient 4268 are set forth in Table 29 below.

TABLE 29

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	2	2.1%
CDR3beta	87	90.6%
4268-TCR5 pairs	2	2.1%
Total paired TCRs	17	17.7%

EXAMPLE 10

[0232] This example demonstrates the identification of anti-mutated p53 T cells in Patient 4266 by co-culturing autologous APCs induced to express mutated p53 within autologous T cells (“p53 hotspot mutation universal screening”). This example also demonstrates the isolation of four anti-mutated p53 TCRs from patient 4266.

[0233] Experiments were carried out as described for Figures 25-31 for Patient 4266.

[0234] TIL fragments (F1-F24, n=24) from patient 4266 were co-cultured with autologous APCs electroporated with TMG composed of irrelevant, WT p53, or mutated p53 sequence. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 25. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes \rightarrow living cells (PI negative) \rightarrow CD3+ (T cells). The results are shown in Figure 26.

[0235] TIL fragments (F1-F24, n=24) from patient 4266 were co-cultured with autologous APCs pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25-amino acid peptides composed of WT p53-R248 sequence or mutated p53-R248W sequence. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 27. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes \rightarrow living cells (PI negative) \rightarrow CD3+ (T cells). The results are shown in Figure 28.

[0236] Cos7 cells (2.5×10^4 per well) were plated on wells of flat-bottom 96 well plates. The following day, cells were co-transfected with individual HLA alleles from patient 4266. The next day cells were pulsed with no peptide, DMSO, WT p53-R248 peptide SSCMGGMNR (SEQ ID NO: 590) or mutated p53-R248W peptide SSCMGGMNWR (SEQ ID NO: 591) for 2 hours at 37 °C at 1 μ g/mL. TIL cultures from patient 4266 (10^5) were added to wells and co-cultured overnight at 37°C. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes \rightarrow living cells (PI negative) \rightarrow CD3+ (T cells) \rightarrow CD4-CD8+. The results are shown in Fig. 29.

[0237] T cells expressing mock (no TCR), 4266-TCR1, 4266-TCR2, 4266-TCR3 or 4266-TCR4 with putative specificity to p53-R248W identified from 4266-TIL were co-cultured with autologous APCs which were pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R248 sequence or mutated p53-R248W sequence. Media alone and PMA and Ionomycin were negative and positive controls, respectively. Co-cultures were performed overnight at 37 °C. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes \rightarrow living cells (PI negative) \rightarrow CD3+ (T cells) \rightarrow CD4-CD8+. The results are shown in Fig. 30.

[0238] A tumor cell (TC) line was established from a xenografted tumor fragment resected from Patient 4266 then serially passaged through immunocompromised mice (TC#4266). The TC#4266 was co-cultured with T cells (10^5) expressing mock (no TCR) or

p53-R248W-specific TCRs (4266-TCR2, 4266-TCR3 or 4266-TCR4) overnight at 37°C. The TC#4266 cells were either incubated with nothing, W6/32 pan-HLA Class-I specific blocking antibody, IVA12 pan-HLA Class-II specific blocking antibody or mutated p53-R248W peptide SSCMGGMNWR (SEQ ID NO: 591) for 2 hours at 37 °C. The antibodies were kept in the co-culture at 5 µg/mL final concentration. The peptide was incubated at 1 µg/mL and excess peptide was washed after incubation. Media alone (no TC) and PMA and Ionomycin were negative and positive controls, respectively. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes → living cells (PI negative) → CD3+ (T cells) → CD4-CD8+. The results are shown in Fig. 31.

[0239] The sequence of **4266-TCR1**, which was isolated from Patient 4266, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 97), the second underlined region is the CDR2alpha (SEQ ID NO: 98), the third underlined region is the CDR3alpha (SEQ ID NO: 99), the fourth underlined region is the CDR1beta (SEQ ID NO: 100), the fifth underlined region is the CDR2beta (SEQ ID NO: 101), and the sixth underlined region is the CDR3beta (SEQ ID NO: 102). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 103) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 104) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 105) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 106) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0240] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4266-TCR1

Recognition of p53 mutation: R248W

Screening method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: Co-culture 4266-F1, 4266-F3, 4266-F5 and 4266-F6 with p53mutTMG or R248W long peptide (both co-cultures detected the same TCR), sorted CD8+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 17.0% (observed 9 times of 53 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MALLLVPAFQVIFTLGGTRAQSVTQLDSQVPVFEEAPVELRCNYSSSVSVYLFWYVQ
 YPNQGLQLLLKYLSGSTLVESINGFEAEFNKSQTSFHLRKPSVHISDTAEYFCAVSDL
VRDDKIIFGKGTRLHILPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTF
*ITDKCVLDMKAMD*SKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCD*ATLTEKSFETD*
 MNLNFQNLVIVLRILLKLVAGFNLLMTLRLWSSRAKRSGSGATNFSLLKQAGDVEEN
PGPMHIGLLCCVAFSLLWASPVNAGVTQTPKFQVLKTGQSMTLQCAQDMNHNSMY
 WYRQDPGMGLRLIYYSASEGTTDKGEVPNGYNVSRLNKREFSLRLESAAPSQTSVYF
CASIGGFEAFFGQGTRLTVVEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDH
 VELSWWWNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCVQVFHGL
 SEEDKWPEGSPKPVTONISAEAWGRADCGITSASYQOGVLSATILYEILLGKATLYAVLVSTL
 VVMAMVKRKNS (SEQ ID NO: 583)

[0241] The statistics for TCR **4266-TCR1** of Patient 4266 are set forth in Table 30 below.

TABLE 30

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	9	9.4%
CDR3beta	10	10.4%
4266-TCR1 pairs	9	9.4%
Total paired TCRs	53	55.2%

[0242] The sequence of **4266-TCR2**, which was isolated from Patient 4266, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 107), the second underlined region is the CDR2alpha (SEQ ID NO: 108), the third underlined region is the CDR3alpha (SEQ ID NO: 109), the fourth underlined region is the CDR1beta (SEQ ID NO: 110), the fifth underlined region is the CDR2beta (SEQ ID NO: 111), and the sixth underlined region is the CDR3beta (SEQ ID NO: 112). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 113) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 114) includes the sequence starting immediately after the linker and ending immediately prior to

the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 115) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 116) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0243] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4266-TCR2

Recognition of p53 mutation: R248W

Screening method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: Co-culture 4266-F1, 4266-F3, 4266-F5 and 4266-F6 with p53mutTMG or R248W long peptide (both co-cultures detected the same TCR), sorted CD8+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 24.5% (observed 13 times of 53 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAGVFLLYVSMKMGTTGQNIDQPTMTATEGAIVQINCTYQTSGFNGLFWYQQH
 AGEAPTFLSYNVLDGLEEKGRFSSFLSRSKGYSYLLKELQMKDSASYLCAVYTGGF
 KTIFGAGTRLFVKANIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITD
 KCVLDMKAMD SKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLLEKSFETDMNL
 NFQNLLVIVLRILLKLVAGFNLLMTLRLWSSRAKRSGSGATNFSLLKQAGDVEENPGP
 MHTRLLCWAALCLLGAELTEAGVAQSPRYKIIEKRQSVAFWCNPISGHATLYWYQQ
 ILGQGPKLLIQFQNGVVDDSQLPKDRFSAERLKGVDSTLKIQPAKLEDSAVYLCAS
 NLGGGSTDTQYFGPGTRLTVLEDLRNVTPPKVSLFEPKAEIANKQKATLVCLARGFFP
 DHVELSWWWNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNP RNHFRCQVQFH
 GLSEEDKWPEGSPKPVTONISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLV
 STLVVMAMVKRKNS (SEQ ID NO: 584)

[0244] The statistics for TCR **4266-TCR2** of Patient 4266 are set forth in Table 31 below.

TABLE 31

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	21	21.9%
CDR3beta	18	18.8%
4266-TCR2 pairs	13	13.5%
Total paired TCRs	53	55.2%

[0245] The sequence of **4266-TCR3**, which was isolated from Patient 4266, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 117), the second underlined region is the CDR2alpha (SEQ ID NO: 118), the third underlined region is the CDR3alpha (SEQ ID NO: 119), the fourth underlined region is the CDR1beta (SEQ ID NO: 120), the fifth underlined region is the CDR2beta (SEQ ID NO: 121), and the sixth underlined region is the CDR3beta (SEQ ID NO: 122). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 123) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 124) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 125) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 126) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0246] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4266-TCR3

Recognition of p53 mutation: R248W

Screening method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: Co-culture 4266-F1, 4266-F3, 4266-F5 and 4266-F6 with p53mutTMG or R248W long peptide (both co-cultures detected the same TCR), sorted CD8+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 34.0% (observed 18 times of 53 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAGVFLLYVSMKMGGTTGQNIDQPTEMTATEGAIVQINCTYQTSGFNGLFWYQQH
 AGEAPTFLSYNVLDGLEEKGRFSSFLSRKGYSYLLKELQMKDSASYLCAFYYGGS
QGNLIFGKGTKLSVKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFIT
 DKCVLDMKAMD~~SKSNGAIAWSNQT~~SFTCQDIFKETNATYPSSDVPCD~~ATL~~TEKSFETDMN
 LNFQNLVIVLRILLKLVAGFNLLMTLRLWSS**RAKRSGSGATNF**SLLK**QAGDVEENPG**
 PMHTRLLCWVVLGFLGTDHTGAGVVSQSPRYKVAKRGQDVALRCDPISGHVSLFWY
 QQALGQGPEFLTYFQNEAQLDKSGLPSDRFFAERPEGSVSTLKIQR~~TQ~~EDSAVYLC
ASSFGSGSTDTQYFGPGTRLTVLEDLRNVTPKVSLFEP**SKAEIANKQKATLVCLARGFF**
 PDHVELSWVWNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNP**RNHFR**CQVQF
 HGLSEEDKWPEGSPKPVTQ**NISAEAWGRADCGITSASYQ**QGVLSATILYEILLG**KATLYAVL**
 VSTLVVMAMV**KRKNS** (SEQ ID NO: 585)

[0247] The statistics for TCR **4266-TCR3** of Patient 4266 are set forth in Table 32 below.

TABLE 32

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	19	19.8%
CDR3beta	26	27.1
4266-TCR3 pairs	18	18.8%
Total paired TCRs	53	55.2%

[0248] The sequence of **4266-TCR4**, which was isolated from Patient 4266, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 127), the second underlined region is the CDR2alpha (SEQ ID NO: 128), the third underlined region is the CDR3alpha (SEQ ID NO: 129), the fourth underlined region is the CDR1beta (SEQ ID NO: 130), the fifth underlined region is the CDR2beta (SEQ ID NO: 131), and the sixth underlined region is the CDR3beta (SEQ ID NO: 132). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta

chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 133) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 134) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 135) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 136) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0249] Cancer reactive T cells were identified using the screening method set forth below. The method used to isolate the TCR is set forth below.

TCR name: 4266-TCR4

Recognition of p53 mutation: R248W

Screening method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: Co-culture 4266-F1, 4266-F3, 4266-F5 and 4266-F6 with p53mutTMG or R248W long peptide (both co-cultures detected the same TCR), sorted CD8+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 9.4% (observed 5 times of 53 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAGVFLLYVSMKMGTTGQNIQDQPTMTATEGAIVQINCTYQTSGFNGLFWYQQH
 AGEAPTFLSYNVLDGLEEKGRFSSFLSRKGYSYLLKELQMKDSASYLCAVYPGGS
QGNLIFGKGTKLSVKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFIT
 DKCVLDMKAMD~~SKS~~NGAIAWSNQTSTFCQDIFKETNATYPSSDVPCD~~ATL~~TEKSFETDMN
 LNFQNLVIVLRILLKLVAGFNLLMTLRLWSSRAKRSGSGATNFSLLKQAGDVEENPG
 PMHTRLLCWAALCLLGAELTEAGVAQSPRYKIIKRQSVAFWCNPISGHATLYWYQ
 QILGQGPKLLIQFQNGVVDDSQLPKDRFSAERLKGVDSTLKIQPAKLEDSAVYLCA
SSLGTGSDTQYFGPGTRLTVLEDLRNVTPPKVSLFEPKAEIANKQKATLVCLARGFFP
 DHVELSWVWNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNP~~RNH~~FRCQVQFH
 GLSEEDKWPEGSPKPVTONISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLV
 STLVVMAMVKKRNS (SEQ ID NO: 586)

[0250] The statistics for TCR 4266-TCR4 of Patient 4266 are set forth in Table 33 below.

TABLE 33

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	5	5.2%

Parameter	#	Frequency
CDR3beta	13	13.5
4266-TCR3 pairs	5	5.2%
Total paired TCRs	53	55.2%

EXAMPLE 11

[0251] This example demonstrates the identification of anti-mutated p53 T cells in Patient 4252 by co-culturing autologous APCs induced to express mutated p53 within autologous T cells (“p53 hotspot mutation universal screening”).

[0252] TIL fragments F1, F3, F7 and F19 patient 4252 were used as effectors. Co-cultures with T cell effectors and autologous APCs (immature DCs) were either (1) electroporated with TMGs composed of irrelevant, WT p53 or mutated p53 sequences or (2) pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R175 sequence or mutated p53-R175H sequence. T cells only (no target) was negative control and PMA and Iono was positive control. Co-cultures were performed overnight at 37 °C. Expression of 4-1BB on CD3+CD8-CD4+ T cells was evaluated by flow cytometry. The results are shown in Figure 38.

EXAMPLE 12

[0253] This example demonstrates the identification of anti-mutated p53 T cells in Patient 4270 by co-culturing autologous APCs induced to express mutated p53 within autologous T cells (“p53 hotspot mutation universal screening”).

[0254] TIL fragments F13 and F16 patient 4270 were used as effectors. Co-cultures with T cell effectors and autologous APCs (immature DCs) were either (1) electroporated with TMGs composed of irrelevant, WT p53 or mutated p53 sequences or (2) pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R282 sequence or mutated p53-R282W sequence. T cells only was negative control and PMA and Iono was positive control. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 39.

EXAMPLE 13

[0255] This example demonstrates the identification of anti-mutated p53 T cells in Patient 4285 by co-culturing autologous APCs induced to express mutated p53 within autologous T cells (“p53 hotspot mutation universal screening”).

[0256] TIL fragments (F1-F22 and F24, n=18) from patient 4285 were co-cultured with autologous APCs electroporated with TMGs composed of irrelevant, WT p53 or mutated p53 sequences. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 40. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes \rightarrow living cells (PI negative) \rightarrow CD3+ (T cells). The results are shown in Figure 42.

[0257] TIL fragments (F1-F22 and F24, n=18) from patient 4285 were co-cultured with autologous APCs pulsed with peptide vehicle (DMSO) or purified (>95% by HPLC) 25 amino acid peptides composed of WT p53-R175 sequence or mutated p53-R175H sequence. Co-cultures were performed overnight at 37 °C. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Figure 41. Expression of 4-1BB was evaluated by flow cytometry after gating for lymphocytes \rightarrow living cells (PI negative) \rightarrow CD3+ (T cells). The results are shown Figure 43.

[0258] Autologous APCs were pulsed with 15-amino acid peptides from the p53-R175H sequence (amino acid substitution underlined in Table 34) overlapping 14 amino acids. TIL from patient 4285 (fragment cultures 10, 6 and 9) with specificity to p53-R175H were co-cultured overnight at 37 °C with peptide-pulsed APCs. DMSO was peptide vehicle. Secretion of IFN- γ was evaluated using ELISPOT assay. The results are shown in Table 34.

TABLE 34

		ELISPOT Result		
		Positive (+) or negative (-) for IFN-γ production		
Peptide	SEQ ID NO:	4285-F10	4285-F6	4285-F9
None (vehicle)	Not applicable	-	-	-
YKQSQHMT <u>E</u> VVR <u>H</u> CP	519	-	-	-
KQSQHMT <u>E</u> VVR <u>H</u> CPH	520	-	-	+
QSQHMT <u>E</u> VVR <u>H</u> CPHH	521	-	+	+

		ELISPOT Result		
		Positive (+) or negative (-) for IFN-γ production		
Peptide	SEQ ID NO:	4285-F10	4285-F6	4285-F9
SQHMTEVVR <u>H</u> CPHHE	522	+	+	+
QHMTEVVR <u>H</u> CPHHER	523	+	+	+
HMTEVVR <u>H</u> CPHHERC	524	+	+	+
MTEVVR <u>H</u> CPHHERCS	525	+	+	+
TEVVR <u>H</u> CPHHERCSD	526	+	+	+
EVVR <u>H</u> CPHHERCSDS	527	+	+	+
VVR <u>H</u> CPHHERCSDSD	528	+	+	-
VR <u>H</u> CPHHERCSDSDG	529	+	+	-

[0259] Cos7 cells (2.5×10^4 per well) were plated on wells of flat-bottom 96 well plates. The following day, cells were co-transfected with individual HLA alleles from patient 4285. The next day cells were pulsed with DMSO or mutated p53-R175H peptide YKQSQHMTEVVRHCPHHERCSDSDG (SEQ ID NO: 2) for 2 hours at 37 °C at 10 μ g/mL. Selected TIL fragment cultures with specificity to p53-R175H from Patient 4285 (4285-F6, 4285-F9 and 4285-F10) were co-cultured with transfected Cos7 cells overnight at 37 °C. Expression of 4-1BB was assayed by flow cytometry after gating lymphocytes \rightarrow live \rightarrow CD3+ (T cells) \rightarrow CD8-CD4+. The results are shown in Figure 54.

[0260] Autologous APCs were pulsed with decreasing concentrations of 25- or 15-amino acid peptides corresponding to the WT or mutated p53-R175H sequence for 2 hours at 37 °C. T cells transposed with 4285-TCR1 from patient 4285 were co-cultured overnight at 37 °C with peptide-pulsed APCs. Expression of 4-1BB was assayed by flow cytometry after gating lymphocytes \rightarrow live \rightarrow CD3+ (T cells) \rightarrow CD8-CD4+. The results are shown in Figure 55.

[0261] The sequence of **4285-TCR1**, which was isolated from Patient 4285, is set forth below. Starting from the amino terminus, the first underlined region is the CDR1alpha (SEQ ID NO: 487), the second underlined region is the CDR2alpha (SEQ ID NO: 488), the third underlined region is the CDR3alpha (SEQ ID NO: 489), the fourth underlined region is the CDR1beta (SEQ ID NO: 490), the fifth underlined region is the CDR2beta (SEQ ID NO: 491), and the sixth underlined region is the CDR3beta (SEQ ID NO: 492). The bold region is the linker (SEQ ID NO: 26). Starting from the amino terminus, the first italicized region is

the alpha chain constant region (SEQ ID NO: 23) and the second italicized region is the beta chain constant region (SEQ ID NO: 25). The alpha chain variable region (SEQ ID NO: 493) includes the sequence starting from the amino terminus and ending immediately prior to the start of the alpha chain constant region. The beta chain variable region (SEQ ID NO: 494) includes the sequence starting immediately after the linker and ending immediately prior to the start of the beta chain constant region. The full-length alpha chain (SEQ ID NO: 495) includes the sequence starting from the amino terminus and ending immediately prior to the start of the linker. The full-length beta chain (SEQ ID NO: 496) includes the sequence starting immediately after the linker and ending with the carboxyl terminus.

[0262] Cancer reactive T cells were identified as described below. The TCR was isolated as described below.

TCR name: 4285-TCR1

Recognition of p53 mutation: R175H

Screening method: p53 “hotspot” mutation universal screening

Co-culture to identify TCR: Co-culture 4285-F6 with p53-R175H peptide and sorted CD4+41BB+ T cells

Method to identify TCR: single-cell RT-PCR

Abundance of TCR amongst all paired TCRs: 81.8% (observed 36 times of 44 pairs)

TCR orientation: alpha-beta

Expression vector: SB transposon

MAKNPLAAPLLILWFHLDCVSSILNVEQSPQSLHVQEGDSTNFTCSFPSSNFYALHWY
 RWETAKSPEALFVMTLNGDEK~~KK~~GRISATLNTKEGYSYLYIKGSQPEDSATYLCALI
 TGGGNKLTFTGTQLKVELNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMES
 GTFITDKCVLDMKAMD~~SKS~~NGAIAWSNQTSTFCQDIFKETNATYPSSDVPCDATLTEKSFE
 TDMNLNFQ~~NLL~~VIVLRILL~~LL~~KVAGFNLLMTLRLWSSRAKRS~~SG~~GATNFSLLKQAGDVE
 ENPGPMHLGLLCCGAFSLLWAGPVNAGVTQTPKFRVLKTGQSM~~TL~~LCAQDMNHEY
 MYWYRQDPGMGLRLIHYSVGE~~GT~~TAKGEVPDGYNVSRLLKQNFLGLESAAPSQTS
 VYFCASRLQGWNSPLHFGNGTRLTVTE~~DL~~RNVTPPKVSLFEP~~SKAE~~IANKQKATLVCLA
 RGFFPDHVELSWVNGKEVHSGVCTDPQAYKESNYSYCLSSRLRVSATFWHNP~~R~~NHFRC
 QVQFHGLSEEDKWPEGSPK~~PVT~~QNISAEAWGRADCGITSASYQ~~Q~~GVLSATILYEILLGKAT
 LYAVLVSTLVVMAMV~~K~~RKNS (SEQ ID NO: 589)

[0263] The statistics for 4285-TCR1 from patient 4285 are set forth in Table 35.

TABLE 35

Parameter	#	Frequency
Total wells	96	100%
CDR3alpha	37	39.8%
CDR3beta	39	40.6%

Parameter	#	Frequency
4285-TCR1 pairs	36	37.5%
Total paired TCRs	44	45.8%

EXAMPLE 14

[0264] This example demonstrates a summary of responses to p53 “hotspot” mutations by T cells.

[0265] A summary of responses to p53 “hotspot” mutations by T cells is provided in Table 36. Numbers 1-15 of Table 36 were a retrospective study. Numbers 16-33 of Table 36 were a prospective study.

TABLE 36

#	Tumor type	Patient	p53 mut	T cell screen	HLA
1	Gastric	3446	G245S	n/a	n/a
2	Gastroesophageal	3788	Y220C	N	n/a
3	Rectal	3942	R273C	n/a	n/a
4	Colon	4023	R282W	Y	Class-II
5	Colon	4095	R282W	n/a	n/a
6	Ovarian	4127	G245S	Y	DRB3*02:02
7	Breast	4130	R273H	Y	Class-II
8	Colon	4141	R175H	Y	A*02:01
9	Ovarian	4149	Y220C	Y	DRB3*02:02
10	Colon	4160	R273H	N	n/a
11	Melanoma	4165	G245D	N	n/a
12	Colon	4166	R248W	n/a	n/a
13	Rectal	4171	R248Q	N	n/a
14	Melanoma	4187	R273H	N	n/a
15	Colon	4196	R175H	Y	A*02:01
16	Colon	4213	R248Q	Y	both
17	Colon	4217	R175H	N	n/a

#	Tumor type	Patient	p53 mut	T cell screen	HLA
18	Cholangiocarcinoma	4220	R248Q	N	n/a
19	Rectal	4235	R273C	N	n/a
20	Colon	4238	R248Q	Y	Class-I
21	Colon	4244	R282W	N	n/a
22	Colon	4245	R248Q	N	n/a
23	Colon	4252	R175H	N	n/a
24	Melanoma	4253	R248W	Y	unknown
25	Colon	4254	R273H	N	n/a
26	Colon	4257	R248W	N	n/a
27	Endometrial	4258	R273H	N	n/a
28	Colon	4259	Y220C	Y	A*02:01, DRB1*04
29	Colon	4266	R248W	Y	A*68:01
30	Colon	4268	R248Q	Y	both
31	Pancreatic	4270	R282W	Y	unknown
32	Rectal	4273	R248W	Y	DPB1*02:01
33	Rectal	4274	R175H	n/a	
34	Colon	4283	R175H	N	n/a
35	Colon	4285	R175H	Y	DRB1*13:01
36	Colon	4287	R248W	N	n/a
37	Colon	4312	R175H	N	n/a

n/a=not applicable; N=negative; Y=confirmed reactive; TBS=to be screened.

EXAMPLE 15

[0266] This example demonstrates the treatment of patients with p53 mutation-reactive TIL.

[0267] A summary of the treatment of patients with p53 mutation-reactive TIL is provided in Table 37.

TABLE 37

#	Tumor Type	Patient	p53 mut	Infusion bag screening	Total # of Cells ($\times 10^9$)	% of p53 reactive TIL	# of p53 reactive TIL ($\times 10^9$)	Response	Duration (months)
1	Ovarian	4127	G245S	Y	143	2.8	4.0	P.R.	4
2	Colon	4141	R175H	Y	69	0.8	0.6	N.R.	-
3	Colon	4196	R175H	Y	92	3.3	3.0	N.R.	-
4	Ovarian	4149	Y220C	Y	37	11.1	4.1	N.R.	-
5	Colon	4213	R248Q	TBS	33			P.R.	4
6	Colon	4238	R248Q	TBS	57			N.R.	
7	Colon	4266	R248W	Y	104	50.8	52.8		
8	Colon	4268	R248Q	**TBS					
9	Rectal	4273	R248W	**Y	117	6.8	8.0	N.R.	-
10	Colon	4285	R175H	Y	69.6	2.4	1.7	N.R.	-

NT=not treated; TBS=to be screened; N.R.=no response; P.R.=partial response; **patient not yet treated.

EXAMPLE 16

[0268] This example demonstrates the overall frequencies of each missense p53 mutation in all of the tumors sequenced.

[0269] Samples were acquired as follows: Tumor and PBL were collected from 141 cancer patients. TIL were grown from tumors. Tumor samples underwent exome and transcriptome sequencing. Tp53 mutations were identified. Out of 150 tumors, 30% expressed WT p53, and 70% expressed mutated p53. Out of 122 tumor samples which expressed mutated p53, 73% expressed a missense mutation, 13% expressed a stop-gain mutation, 11% expressed a frameshift mutation, and 3% expressed an indel mutation.

[0270] The overall frequencies of each missense p53 mutation in all of the tumors sequenced are shown in Figure 44.

EXAMPLE 17

[0271] This example demonstrates a summary of the reactivity of TCRs of Examples 1-15.

[0272] The TCRs of Table 38 were isolated, expressed in T cells and tested against the relevant antigen. A summary of the results is shown in Table 38.

TABLE 38

TCR name	p53 a.a. substitution	TCR tested?	p53 mutation reactive?
4127-TP53-G245S-TCR1	G245S	yes	yes
4149TCRa2b2	Y220C	yes	yes
4266-TCR1	R248W	yes	no
4266-TCR2	R248W	yes	yes
4266-TCR3	R248W	yes	yes
4266-TCR4	R248W	yes	yes
4268-TCR1	R248Q	yes	no
4268-TCR2	R248Q	yes	no
4268-TCR3	R248Q	yes	no
4268-TCR4	R248Q	yes	no
4268-TCR5	R248Q	yes	no
4273-TP53-R248W-TCR1a1	R248W	yes	no
4273-TP53-R248W-TCR1a2	R248W	yes	Yes
4141-TCR1a2	R175H	yes	yes

TCR name	p53 a.a. substitution	TCR tested?	p53 mutation reactive?
4285-TCR1	R175H	yes	yes
4259-F6-TCR	Y220C	yes	yes
4127-O37-TCR	G245S	yes	yes

[0273] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0274] The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0275] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the

foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

CLAIM(S):

1. A method of isolating T cells having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising:

inducing autologous antigen presenting cells (APCs) of a patient to present at least one mutated p53 amino acid sequence;

co-culturing autologous T cells of the patient with the autologous APCs that present the mutated p53 amino acid sequence; and

selecting the autologous T cells that (a) were co-cultured with the autologous APCs that present the mutated p53 amino acid sequence and (b) have antigenic specificity for the mutated p53 amino acid sequence presented in the context of a major histocompatibility complex (MHC) molecule expressed by the patient to provide isolated T cells having antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation.

2. The method of claim 1, wherein inducing autologous APCs of the patient to present the mutated p53 amino acid sequence comprises pulsing APCs with a peptide comprising the mutated p53 amino acid sequence or a pool of peptides, each peptide in the pool comprising a different mutated p53 amino acid sequence.

3. The method of claim 2, wherein the peptide or pool of peptides comprise(s) one or more mutated p53 peptides of SEQ ID NOs: 2-13.

3. The method of claim 1, wherein inducing autologous APCs of the patient to present the mutated p53 amino acid sequence comprises introducing a nucleotide sequence encoding the mutated p53 amino acid sequence into the APCs.

4. The method of claim 3, wherein the nucleotide sequence introduced into the autologous APCs is a tandem minigene (TMG) construct, each minigene comprising a p53 gene, each p53 gene including a cancer-specific p53 mutation that encodes a mutated p53 amino acid sequence, wherein each p53 gene in the TMG construct encodes a different mutated p53 amino acid sequence.

5. The method of claim 4, wherein the TMG construct encodes one or more mutated p53 peptides of SEQ ID NOs: 2-13.

6. The method of claim 4, wherein the TMG construct encodes the amino acid sequence of SEQ ID NO: 14.

7. The method of any one of claims 1-6, wherein selecting the autologous T cells that have antigenic specificity for the mutated p53 amino acid sequence comprises selectively growing the autologous T cells that have antigenic specificity for the mutated p53 amino acid sequence.

8. The method of any one of claims 1-7, wherein selecting the autologous T cells that have antigenic specificity for the mutated p53 amino acid sequence comprises selecting the T cells that express any one or more of programmed cell death 1 (PD-1), lymphocyte-activation gene 3 (LAG-3), T cell immunoglobulin and mucin domain 3 (TIM-3), 4-1BB, OX40, and CD107a.

9. The method of any one of claims 1-8, wherein selecting the autologous T cells that have antigenic specificity for the mutated p53 amino acid sequence comprises selecting the T cells (i) that secrete a greater amount of one or more cytokines upon co-culture with APCs that present the mutated p53 amino acid sequence as compared to the amount of the one or more cytokines secreted by a negative control or (ii) in which at least twice as many of the numbers of T cells secrete one or more cytokines upon co-culture with APCs that present the mutated p53 amino acid sequence as compared to the numbers of negative control T cells that secrete the one or more cytokines.

10. The method of claim 9, wherein the one or more cytokines comprise interferon (IFN)- γ , interleukin (IL)-2, tumor necrosis factor alpha (TNF- α), granulocyte/monocyte colony stimulating factor (GM-CSF), IL-4, IL-5, IL-9, IL-10, IL-17, and IL-22.

11. A method of isolating a T cell receptor (TCR), or an antigen-binding portion thereof, having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising:

isolating T cells having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation according to the method of any one of claims 1-10; and

isolating a nucleotide sequence that encodes the TCR, or the antigen-binding portion thereof, from the selected autologous T cells, wherein the TCR, or the antigen-binding portion thereof, has antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation.

12. A method of preparing a population of cells that express a TCR, or an antigen-binding portion thereof, having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising:

isolating a TCR, or an antigen-binding portion thereof, according to the method of claim 11, and

introducing the nucleotide sequence encoding the isolated TCR, or the antigen-binding portion thereof, into peripheral blood mononuclear cells (PBMC) to obtain cells that express the TCR, or the antigen-binding portion thereof.

13. A method of preparing a population of T cells that have antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising:

isolating T cells according to the method of any one of claims 1-10, and
expanding the numbers of selected autologous T cells to obtain a population of T cells that have antigenic specificity for the mutated p53 amino acid sequence encoded by the cancer-specific p53 mutation.

14. The method of claim 13, wherein expanding the numbers of thereof cells comprises culturing the selected cells with feeder PBMC, interleukin (IL)-2, and OKT3 antibody.

15. An isolated population of cells prepared according to the method of any one of claims 12-14.

16. A pharmaceutical composition comprising the isolated population of cells of claim 15 and a pharmaceutically acceptable carrier.

17. The isolated population of cells of claim 15 or the pharmaceutical composition of claim 16 for use in treating or preventing cancer in a patient.

18. The isolated population of cells or pharmaceutical composition for the use according to claim 17, wherein the cancer is an epithelial cancer.

19. The isolated population of cells or pharmaceutical composition for the use according to claim 17, wherein the cancer is cholangiocarcinoma, melanoma, colon cancer, rectal cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), glioblastoma, uterine cervical cancer, head and neck cancer, breast cancer, pancreatic cancer, or bladder cancer.

20. The isolated population of cells, or a pharmaceutical composition comprising the isolated population of cells, for the use according to any one of claims 17-19, wherein the isolated population of cells is autologous to the patient.

21. The isolated population of cells, or a pharmaceutical composition comprising the isolated population of cells, for the use according to any one of claims 17-19, wherein the isolated population of cells is allogeneic to the patient.




FIG. 1

2/55




FIG. 2

3/55




FIG. 3




FIG. 4




FIG. 5

6/55




FIG. 6

7/55




FIG. 7

8/55




FIG. 8




FIG. 9




FIG. 10

11/55




FIG. 11

12/55




FIG. 12

13/55




FIG. 13




FIG. 14




FIG. 15

16/55




FIG. 16

17/55




FIG. 17

18/55




FIG. 18




FIG. 19

20/55




FIG. 20

21/55




FIG. 21

22/55




FIG. 22

23/55




FIG. 23




FIG. 24

25/55




FIG. 25

26/55




FIG. 26

27/55




FIG. 27

28/55




FIG. 28




FIG. 29

30/55




FIG. 30

31/55




FIG. 31

32/55

CLUSTAL O(1.2.4) multiple sequence alignment

```

SP|P04637|P53_HUMAN MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLSQAMDDLMLSPDDIEQWFTEDPGP 60
SP|P04637-2|P53_HUMAN MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLSQAMDDLMLSPDDIEQWFTEDPGP 60
SP|P04637-3|P53_HUMAN MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLSQAMDDLMLSPDDIEQWFTEDPGP 60
SP|P04637-4|P53_HUMAN -----MDDLMLSPDDIEQWFTEDPGP 21
SP|P04637-5|P53_HUMAN -----MDDLMLSPDDIEQWFTEDPGP 21
SP|P04637-6|P53_HUMAN -----MDDLMLSPDDIEQWFTEDPGP 21
SP|P04637-7|P53_HUMAN -----
SP|P04637-8|P53_HUMAN -----
SP|P04637-9|P53_HUMAN -----

```

```

SP|P04637|P53_HUMAN DEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK 120
SP|P04637-2|P53_HUMAN DEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK 120
SP|P04637-3|P53_HUMAN DEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK 120
SP|P04637-4|P53_HUMAN DEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK 81
SP|P04637-5|P53_HUMAN DEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK 81
SP|P04637-6|P53_HUMAN DEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK 81
SP|P04637-7|P53_HUMAN -----
SP|P04637-8|P53_HUMAN -----
SP|P04637-9|P53_HUMAN -----

```

```

SP|P04637|P53_HUMAN SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTVEVRRCPHHE 180
SP|P04637-2|P53_HUMAN SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTVEVRRCPHHE 180
SP|P04637-3|P53_HUMAN SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTVEVRRCPHHE 180
SP|P04637-4|P53_HUMAN SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTVEVRRCPHHE 141
SP|P04637-5|P53_HUMAN SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTVEVRRCPHHE 141
SP|P04637-6|P53_HUMAN SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTVEVRRCPHHE 141
SP|P04637-7|P53_HUMAN -----MFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTVEVRRCPHHE 48
SP|P04637-8|P53_HUMAN -----MFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTVEVRRCPHHE 48
SP|P04637-9|P53_HUMAN -----MFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTVEVRRCPHHE 48
*****

```

```

SP|P04637|P53_HUMAN RCSDSDGLAPPQHLIRVEGNLRVEYLDNRNTRFHSVVPYEPPEVGSDCCTIIHNYMNCNS 240
SP|P04637-2|P53_HUMAN RCSDSDGLAPPQHLIRVEGNLRVEYLDNRNTRFHSVVPYEPPEVGSDCCTIIHNYMNCNS 240
SP|P04637-3|P53_HUMAN RCSDSDGLAPPQHLIRVEGNLRVEYLDNRNTRFHSVVPYEPPEVGSDCCTIIHNYMNCNS 240
SP|P04637-4|P53_HUMAN RCSDSDGLAPPQHLIRVEGNLRVEYLDNRNTRFHSVVPYEPPEVGSDCCTIIHNYMNCNS 201
SP|P04637-5|P53_HUMAN RCSDSDGLAPPQHLIRVEGNLRVEYLDNRNTRFHSVVPYEPPEVGSDCCTIIHNYMNCNS 201
SP|P04637-6|P53_HUMAN RCSDSDGLAPPQHLIRVEGNLRVEYLDNRNTRFHSVVPYEPPEVGSDCCTIIHNYMNCNS 201
SP|P04637-7|P53_HUMAN RCSDSDGLAPPQHLIRVEGNLRVEYLDNRNTRFHSVVPYEPPEVGSDCCTIIHNYMNCNS 108
SP|P04637-8|P53_HUMAN RCSDSDGLAPPQHLIRVEGNLRVEYLDNRNTRFHSVVPYEPPEVGSDCCTIIHNYMNCNS 108
SP|P04637-9|P53_HUMAN RCSDSDGLAPPQHLIRVEGNLRVEYLDNRNTRFHSVVPYEPPEVGSDCCTIIHNYMNCNS 108
*****

```

```

SP|P04637|P53_HUMAN SCMGGMNRRLPILTIITLEDSSGNLLGRNSFEVRVCACPGDRRTEENLRKKGEPHHELP 300
SP|P04637-2|P53_HUMAN SCMGGMNRRLPILTIITLEDSSGNLLGRNSFEVRVCACPGDRRTEENLRKKGEPHHELP 300
SP|P04637-3|P53_HUMAN SCMGGMNRRLPILTIITLEDSSGNLLGRNSFEVRVCACPGDRRTEENLRKKGEPHHELP 300
SP|P04637-4|P53_HUMAN SCMGGMNRRLPILTIITLEDSSGNLLGRNSFEVRVCACPGDRRTEENLRKKGEPHHELP 261
SP|P04637-5|P53_HUMAN SCMGGMNRRLPILTIITLEDSSGNLLGRNSFEVRVCACPGDRRTEENLRKKGEPHHELP 261
SP|P04637-6|P53_HUMAN SCMGGMNRRLPILTIITLEDSSGNLLGRNSFEVRVCACPGDRRTEENLRKKGEPHHELP 261
SP|P04637-7|P53_HUMAN SCMGGMNRRLPILTIITLEDSSGNLLGRNSFEVRVCACPGDRRTEENLRKKGEPHHELP 168
SP|P04637-8|P53_HUMAN SCMGGMNRRLPILTIITLEDSSGNLLGRNSFEVRVCACPGDRRTEENLRKKGEPHHELP 168
SP|P04637-9|P53_HUMAN SCMGGMNRRLPILTIITLEDSSGNLLGRNSFEVRVCACPGDRRTEENLRKKGEPHHELP 168
*****

```

```

SP|P04637|P53_HUMAN PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKAQAGKEPG 360
SP|P04637-2|P53_HUMAN PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQDQTSFQKENC----- 341
SP|P04637-3|P53_HUMAN PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQMLLDLRWCYFLINSS----- 346
SP|P04637-4|P53_HUMAN PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKAQAGKEPG 321
SP|P04637-5|P53_HUMAN PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQDQTSFQKENC----- 302
SP|P04637-6|P53_HUMAN PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQMLLDLRWCYFLINSS----- 307
SP|P04637-7|P53_HUMAN PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKAQAGKEPG 228
SP|P04637-8|P53_HUMAN PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQDQTSFQKENC----- 209
SP|P04637-9|P53_HUMAN PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQMLLDLRWCYFLINSS----- 214
*****

```

```

SP|P04637|P53_HUMAN GSRAHSSHLKSKKGQSTS RHKKLMFKTEGPDSD 393
SP|P04637-2|P53_HUMAN -----
SP|P04637-3|P53_HUMAN -----
SP|P04637-4|P53_HUMAN GSRAHSSHLKSKKGQSTS RHKKLMFKTEGPDSD 354
SP|P04637-5|P53_HUMAN -----
SP|P04637-6|P53_HUMAN -----
SP|P04637-7|P53_HUMAN GSRAHSSHLKSKKGQSTS RHKKLMFKTEGPDSD 261
SP|P04637-8|P53_HUMAN -----
SP|P04637-9|P53_HUMAN -----

```

FIG. 32




FIG. 33

34/55




FIG. 34

35/55




FIG. 35




FIG. 36

37/55




FIG. 37




FIG. 38

39/55




FIG. 39

40/55




FIG. 40

41/55




FIG. 41

42/55




FIG. 42

43/55




FIG. 43

44/55




FIG. 44




FIG. 45

46/55




FIG. 46




FIG. 47

48/55




FIG. 48

49/55




FIG. 49




FIG. 50

51/55




FIG. 51




FIG. 52




FIG. 53

54/55




FIG. 54

55/55




FIG. 55

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2018/051280

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12N5/0783 C12N5/0784 A61K35/17 A61K39/00 C07K14/47
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, WPI Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KATERINA SHAMALOV ET AL: "The mutational status of p53 can influence its recognition by human T-cells", ONCOIMMUNOLOGY, vol. 6, no. 4, 31 January 2017 (2017-01-31), page e1285990, XP055523658, DOI: 10.1080/2162402X.2017.1285990	15-21
A	abstract ----- -/--	1-14

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 14 November 2018	Date of mailing of the international search report 28/11/2018
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Loubradou-Bourges, N

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2018/051280

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>INGE MARIE SVANE ET AL: "Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 56, no. 9, 7 February 2007 (2007-02-07), pages 1485-1499, XP019514194, ISSN: 1432-0851, DOI: 10.1007/S00262-007-0293-4</p>	15-21
A	<p>abstract</p>	1-14
A	<p>-----</p> <p>ALENA GROS ET AL: "Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients", NATURE MEDICINE, vol. 22, no. 4, 22 February 2016 (2016-02-22), pages 433-438, XP055460267, New York ISSN: 1078-8956, DOI: 10.1038/nm.4051</p> <p>abstract</p>	1-14
A	<p>-----</p> <p>CYRILLE J. COHEN ET AL: "Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes", JOURNAL OF CLINICAL INVESTIGATION, vol. 125, no. 10, 21 September 2015 (2015-09-21), pages 3981-3991, XP055365967, ISSN: 0021-9738, DOI: 10.1172/JCI82416</p> <p>abstract</p>	1-14
A	<p>-----</p> <p>YONG-CHEN LU ET AL: "Cancer immunotherapy targeting neoantigens", SEMINARS IN IMMUNOLOGY., vol. 28, no. 1, 30 November 2015 (2015-11-30), pages 22-27, XP055364718, US ISSN: 1044-5323, DOI: 10.1016/j.smim.2015.11.002</p> <p>the whole document</p> <p>-----</p> <p style="text-align: center;">-/--</p>	1-21

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2018/051280

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	DREW C. DENIGER ET AL: "T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers", CLINICAL CANCER RESEARCH, 31 May 2018 (2018-05-31), XP055523675, US ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-18-0573 the whole document -----	1-21